 
 Cli ni c al Tri al Pr ot o c ol : T H R- [ADDRESS_664951] u d y Title:  A d o u ble bli n d place b o c o ntr olle d st u d y t o e val u ate t he effect of 
be x a glifl ozi n ta blets o n he m o gl o bi n A 1c i n p atie nts wit h t y pe [ADDRESS_664952] u d y N u m ber:  T H R -[ADDRESS_664953] u d y P h ase:  [ADDRESS_664954] N a me:  Be x a glifl ozi n Ta blets  
I n dic ati o n: T y pe 2 Dia betes M ellit us  
I n vesti g at ors: M ulti -ce nter st u d y 
  
S p o ns or:  T herac os S u b, L L C  
S p o ns or C o nt act:  Tara T h ur ber  Tra nslati o nal Me dici ne Gr o u p Massac h usetts Ge n eral H os pi[INVESTIGATOR_307]  [ADDRESS_664955] o n, M A 0 2 1 1 4 
P h o ne: 6 1 7- 6 4 3- 0 6 9 9 
Fa x: 6 1 7- 6 4 3- 8 2 0 3 E- mail: tt h ur ber @cci b. m g h. har var d. e d u 
Me dic al M o nit or:  A n dre w Alle gretti , M. D., M. Sc 
De part me nt of Ne p hr ol o g y 
Massac h usetts Ge n eral H os pi[INVESTIGATOR_307]  [ADDRESS_664956] o n, M A 0 2 1 1 4 P h o ne:  6 1 7- 7 2 4- 8 0 1 8 Fa x:  6 1 7- 6 4 3- 8 2 0 3 E- mail:  A A L L E G R E T TI @ P A R T N E R S. O R G   
 
 Date  
Versi o n 4. 0:  [ADDRESS_664957] ate me nt  
T he i nf or mati o n i n t his d oc u me nt is c o nfi de ntial i nf or mati o n of T her ac os S u b, L L C 
(“ T her ac os ”) a n d m ust n ot be discl ose d, use d, or c o pie d e x ce pt wit h pri or writte n a p pr o val 
fr o m T her ac os or t o t he e xte nt re q uire d b y a p plica ble l ocal, nati o nal or i nter nati o nal la ws, 
r ules a n d re g ul ati o ns. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664958] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 of 7 2  V 4 ( Gl o bal)  
 T A B L E O F C O N T E N T S  
S Y N O P SI S  ................................................................................................................................. [ADDRESS_664959] u d y Desi g n a n d Pla n  .............................................................................. 1 6  
3. 2 Researc h M et h o ds a n d Pr oce d ur es  ........................................................................ 1 6  
3. 2. 1 Scree ni n g Peri o d  .......................................................................................... 1 6  
3. 2. 2 R u n-i n Peri o d ............................................................................................... 1 6  
3. 2. 3 Treat me nt Peri o d  .......................................................................................... 1 7  
3. 2. 4 Gl yce mic C o ntr ol M o nit ori n g...................................................................... 1 8  
3. 2. 5 O T H E R S A F E T Y M O NI T O RI N G A C TI VI TI E S  ...................................... 1 9  
3. 2. 5. 1  Re nal F u ncti o n ................................................................................... 1 9  
3. 2. 5. 2  Dia betic Ket o aci d osis  ........................................................................ 2 0  
3. 2. 5. 3  Maj or A d vers e Car di o vasc ular E ve nt ( M A C E) ................................. 2 1  
3. 2. 5. 4  Ot her Ge n eral Saf et y M o nit ori n g  ...................................................... 2 1  
3. 2. 6 D A T A A N D S A F E T Y M O NI T O RI N G B O A R D ( D S M B)  ........................ [ADDRESS_664960] u d y P o p ulati o n .................................................................................................... 2 5  
4. 2 I n cl usi o n Criteria ................................................................................................... 2 5  
4. 3 E x cl usi o n Criteria  .................................................................................................. 2 5  
5 S T U D Y T R E A T M E N T S  ................................................................................................. 2 7  
5. 1 Descri pti o n of Tr eat me nts ...................................................................................... 2 7  
5. 2 Treat me nts A d mi nistere d  ....................................................................................... 2 7  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664961] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 of 7 2  V 4 ( Gl o bal)  
 5. 2. [ADDRESS_664962] ................................................................................ 2 7  
5. 2. 2 Bac k gr o u n d Or al H y p o gl yce mic A ge nts ( O H As) ....................................... [ADDRESS_664963] u d y Site .................................................... 3 2  
6 S T U D Y P R O C E D U R E S  ................................................................................................. 3 3  
6. 1 P h o ne I nt er vie w  ..................................................................................................... 3 3  
6. 2 I nf or me d C o nse nt................................................................................................... 3 3  
6. 3 Scree ni n g f or I/ E Criteria  ....................................................................................... [ADDRESS_664964] ora ge, a n d S hi p pi n g .................................................. 3 8  
6. 1 1. 1. 1  He mat ol o g y, Bl o o d C he mistr y, Ser u m Li pi [INVESTIGATOR_805], a n d Gl yce mic 
C o ntr ol Assess me nts .......................................................................... 3 8  
6. 1 1. 1. 2  Uri nal ysis  ........................................................................................... 3 8  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664965] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 of 7 2  V 4 ( Gl o bal)  
 6. [ADDRESS_664966] I nfecti o ns ( U TIs)  ................................................................... 4 5  
6. 1 6. 9  Ge nital M yc otic I nf ecti o ns ( G MIs)  ............................................................. 4 5  
6. 1 6. 1 0  He pat ot o xicit y  .............................................................................................. 4 5  
6. 1 6. 1 1  H y p o gl yce mia  .............................................................................................. 4 6  
6. 1 6. 1 2  Maj or A d vers e Car di o vasc ular E ve nt ( M A C E) ........................................... 4 8  
6. 1 6. 1 3  Dia betic Ket o aci d osis ( D K A)  ...................................................................... [ADDRESS_664967] A d mi nistrati o n  .......................................................................................... 5 0  
6. 1 9 A p pr o priate n ess of Meas ure me nts  ......................................................................... 5 0  
7 S T U D Y A C TI VI TI E S ..................................................................................................... 5 1  
7. 1 Scree ni n g ( 3 d a ys t o 3 w ee ks bef ore r u n -i n peri o d, Visit V 1)............................... 5 1  
7. 2 Visit V 2 ( Start of R u n -i n) ...................................................................................... 5 1  
7. 3 Visit V 3 ( Ra n d o mizati o n)  ...................................................................................... 5 1  
7. 4 Visit V 4 ( wee k 2)  ................................................................................................... 5 2  
7. 5 Visit V 5 ( wee k 6)  ................................................................................................... 5 2  
7. 6 Visit V 6 ( wee k 1 2) ................................................................................................. 5 2  
7. 7 Visit V 7 ( wee k 1 8) ................................................................................................. 5 2  
7. 8 Visit V 8 ( wee k 2 4) ................................................................................................. 5 3  
7. 9 Visit V 9 ( wee k 2 6) ................................................................................................. 5 3  
7. 1 0 Earl y Ter mi nati o n Pr oce d ures ............................................................................... 5 3  
8 Q U A LI T Y C O N T R O L A N D A S S U R A N C E  ................................................................. 5 4  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664968] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 of 7 2  V 4 ( Gl o bal)  
 [ADDRESS_664969] u d y Rec or ds  ................................................................. 6 2  
1 0. 8 Data a n d Saf et y M o nit ori n g B oar d ........................................................................ 6 2  
1 0. 9 Pr ot oc ol Vi olati o ns/ De viati o ns  .............................................................................. [ADDRESS_664970] of La b orat or y T ests  ............................................................................... 3 7  
Ta ble  2.  K D O QI C K D  Sta ges  .................................................................................... 6 8  
Ta ble  3.  Classificati o n/ Sta gi n g S yste m f or Ac ute Ki d ne y I nj ur y  .............................. 6 8  
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664971] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 of 7 2  V 4 ( Gl o bal)  
 LI S T O F I N -T E X T FI G U R E S  
Fi g ure  1.  Re nal F u ncti o n M o nit ori n g Pla n .................................................................. 2 0  
Fi g ure  2.  Gl uc os uria i n patie nts wit h n or mal a n d i m paire d r e nal f u ncti o n ................. 2 3  
 
LI S T O F A P P E N DI C E S  
A p pe n di x 1  Sc he d ule of E ve nts ............................................................................. 6 6  
A p pe n di x 2  Sc he d ule of La b orat or y Tests  ............................................................ 6 7  
A p pe n di x 3  K D O QI C hr o nic Ki d ne y Disease Classificati o n a n d Ac ute 
Ki d ne y I nj ur y Sta ge D efi niti o n .................................................................................... 6 8  
A p pe n di x 4  Esti mati n g G F R a n d C orrecti n g Calci u m  .......................................... 6 9  
A p pe n di x 5  E x a m ples of S G L T 2 I n hi bit ors .......................................................... 7 0  
A p pe n di x 6  S p o ns or Si g nat ures............................................................................. 7 1  
A p pe n di x 7  I n v esti gat or’s Si g n at ure ..................................................................... 7 2  
 
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664972] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 7 of 7 2  V 4 ( Gl o bal)  
 S Y N O P SI S 
S p o ns or : 
T herac os S u b, L L C  
N a me of Fi nis he d Pr o d uct:  
Be x a glifl ozi n Ta blets   
N a me of Acti ve I n gre die nt:  
B e x a glifl ozi n  
St u d y  Title : 
A d o u ble bli n d place b o c o ntr olle d st u d y t o e val u ate t he effect of b e x a glifl o zi n ta blets o n 
he m o gl o bi n A 1c i n p atie nts wit h t y p e [ADDRESS_664973] u d y N u m ber: T H R -[ADDRESS_664974] u d y P h ase:  3  
Pri m ar y O bjecti ve:   
T he pri mar y o bjecti ve of t his st u d y is t o deter mi ne t he efficac y of b e x a glifl ozi n o n l o weri n g 
H b A 1c i n patie nts wit h t y p e 2 di a betes mellit us a n d m o derate r e nal i m pair me nt.  
Sec o n d ar y O bjecti ve s: 
T he ke y sec o n dar y efficac y o bj ecti ves are:  
• T o assess t he effect of be x a glifl ozi n o n t he c ha n ge i n b o d y wei g ht at w ee k 2 4 i n s u bj ects 
wit h baseli ne B MI ≥ 2 5 k g/ m
2 
• T o assess t he effect of be x a glifl ozi n o n t he c ha n ge i n s yst olic bl o o d press ur e ( S B P) at 
wee k 2 4 i n s u bjects wit h baseli ne S B P ≥ 1 3 0 m m H g 
• C ha n ge i n H b A 1c i n s u bj ects wit h e G F R 4 5 t o 5 9 m L/ mi n/ 1. 7 3 m2 at wee k 2 4  
• C ha n ge i n H b A 1c i n s u bj ects wit h e G F R 3 0 t o 4 4 m L/ mi n/ 1. [ADDRESS_664975] u d y Desi g n : 
T H R - [ADDRESS_664976] b o i n s u bjects wit h t y pe 2 dia b etes mellit us  ( T 2 D M), m o derate r e nal i m pair me nt, a n d i na de q uate gl yce mic c o ntr ol. 
Mai n eli gi bilit y criteria i ncl u de: 1) male or fe mal e s u bjects wit h T 2 D M , 2) scree ni n g H b A 1c 
of 7. 0- 1 0. 5 % (i ncl usi ve), a n d 3) esti mate d gl o mer ular filtrati o n rate (e G F R) base d o n ser u m creati ni ne at 2 differ e nt assess me nts ≥ 3 0 t o < 6 0 m L/ mi n/ 1. [ADDRESS_664977] u d y e q uati o n ( M D R D). At t he ti me of scree ni n g, t he d os es a n d fre q ue n c y of all a nti-di a b etic me dicati o ns m ust ha ve bee n sta ble f or [ADDRESS_664978] b o r u n-i n peri o d.  S u bjects w h o are c o m plia nt i n ta ki n g r u n-i n me dicati o n ( missi n g n o m ore t ha n o n e d ose) will be eli gi ble f or ra n d o mizati o n a n d recei ve st u d y dr u g.  
A p pr o xi matel y 3 0 0 s u bj ects of 1 5 0 s u bjects per gr o u p will be ra n d o ml y assi g ne d t o r ecei v e 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664979] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 8 of 7 2  V 4 ( Gl o bal)  
 be x a glifl ozi n ta blets, [ADDRESS_664980] b o , i n e q u al r ati o o nce dail y f or 2 4 wee ks i n a n 
o ut patie nt setti n g. Ra n d o mizati o n will be stratifie d b y scree ni n g H b A 1c le vel ( 7. 0 t o 8. 5 % or 8. 6 t o 1 0. 5 %) , scree ni n g a nti-dia betic treat me nt re gi me n  (i ns uli n treat e d or ot her ) a n d scree ni n g e G F R ( 3 0  t o 4 4 m L/ mi n/ 1. 7 3 m
2 or 4 5 t o 5 9 m L/ mi n/ 1. 7 3 m2). A mi ni mal of [ADDRESS_664981] be i n t he e G F R 3 0 t o 4 4 m L/ mi n/ 1. [ADDRESS_664982] u d y s u bj ects will ha ve sc he d ule d visits at wee ks 2, 6, 1 2, 1 8, a n d 2 4 f or s afet y a n d efficac y 
e val uati o n. At wee ks 2 a n d 1 8, t he visit will be c o n d ucte d a p h o ne i nter vie ws u nless cli nicall y necessar y.  A fi nal f oll o w u p visit will be c o n d ucte d at wee k 2 6. 
Meas ure me nt of be x a glifl ozi n plas ma c o nce ntrati o n o ver ti me (s pars el y s a m pl e d) will als o 
be c o n d ucte d fr o m a p pr o xi matel y [ADDRESS_664983] u d y s u bjects as part of a be x a glifl o zi n p o p ulati o n p har mac o ki netic ( P K) st u d y. 
St u d y P o p ul ati o n :  
T he st u d y p o p ulati o n will c o nsist of [ADDRESS_664984] u d y p o p ulati o n will c o m prise:   1.  Me n or n o n- pr e g na nt w o me n ≥ [ADDRESS_664985] u d y t o a v oi d a n y p ossi ble pr e g na n c y. Fe males w h o ar e s ur gicall y sterile ( h yst erect o m y, o o p h orect o m y) or p ost m e n o pa usal (a bse nce of me ns es greater t ha n 1 2 m o nt hs a n d a ge > 4 5 years) are eli gi ble if t he y test ne gati ve o n t he uri ne pre g na n c y test. 
2.  S u bjects wit h a dia g n osis of T 2 D M wit h a n H b A 1 c bet wee n 7. 0 a n d 1 0. 5 % (i ncl usi ve) at 
t he ti me of scree ni n g. 
3.  S u bjects w h o are tr eat me nt naï ve or ar e treate d wit h a sta ble re gi me n of a nti-dia betic 
me dicati o ns  t hat d o n ot pr o vi de a de q u ate gl yce mi c c o ntr ol w he n c o m bi ne d wit h diet a n d e x ercise.  At t he ti me of scree ni n g, t he d os es a n d fre q ue n c y of all a n ti-di a b etic me dicati o ns m ust ha ve b ee n sta ble f or 8 wee ks . 
4.  S u bjects w h o ha ve a n esti mate d gl o mer ul ar filtrati o n rate ( e G F R) ≥ 3 0 a n d 
< 6 0 m L/ mi n/ 1. 7 3 m
2 at 2 ti me p oi nts: scree ni n g ( V 1), a n d 1 a d diti o nal ti me p oi nt 
bet wee n 1 a n d 1 2 m o nt hs of scree ni n g ( t he m ost rece nt hist orical val ue ma y be o btai ne d fr o m a vaila ble me dical r ec or ds). T h e e G F R  will be calc ul ate d b y t he M D R D e q uati o n.  
5.  S u bjects w h o ha ve a b o d y mass i n de x ( B MI) ≤ 4 5 k g/ m
2 (i ncl usi ve) 
6.  S u bjects w h o ta ki n g sta ble d oses of me dicati o ns f or h y p erte nsi o n or h y p erli pi [INVESTIGATOR_30192] f or at 
least [ADDRESS_664986] oric v al ue  a n d da y of 
scree ni n g ( n o m ore t ha n 2 0 % c ha n ge i n e G F R ).  
Test Pr o d uct, D ose , a n d M o de of A d mi nistr ati o n:   
Be x a glifl ozi n ta blets, [ADDRESS_664987] b o, o nce dail y b y m o ut h 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664988] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 9 of 7 2  V 4 ( Gl o bal)  
 D ur ati o n of Tre at me nt:   
2 5 wee ks: 1 wee k r u n-i n, 2 4 wee ks of tr eat me nt  
Effic ac y Assess me nts:  
Pri mar y efficac y assess me nt:  
• C ha n ge of H b A 1 c fr o m b aseli ne t o wee k 2 4  
 Sec o n dar y efficac y ass ess me nts:  
• C ha n ge i n b o d y wei g ht i n s u bjects wit h baseli ne b o d y mass i n de x ( B MI) ≥ 2 5 k g/ m  
• C ha n ges i n s yst olic bl o o d press ure ( S B P) o ver ti me i n s u bjects wit h baseli ne S B P ≥ 1 3 0 
m m H g  
• C ha n ge i n H b A 1c o v er ti me i n s u bjects wit h e G F R 4 5 t o 5 9 m L/ mi n/ 1. 7 3 m
2 
• C ha n ge i n H b A 1c o v er ti me i n s u bjects wit h e G F R 3 0 t o 4 4 m L/ mi n/ 1. [ADDRESS_664989] e d a n d t he r e q uire d plas ma c o nce ntr ati o ns 
deter mi ne d.  T he P K p ar a meters will be ass esse d se parat el y as part of t h e p o p ulati o n P K a nal ysis.  
S af et y  Assess me nts :  
Safet y will be assesse d b ase d o n a n a n al ysis of t he a d vers e e v e nts rec or d ; of la b orat or y d ata, 
i ncl u di n g he mat ol o g y, ser u m c he mistr y, uri nal ysis, uri nar y electr ol yt es a n d creati ni ne; of electr ocar di o gr a m s ( E C Gs), vital si g ns a n d p h ysi cal e x a mi nati o ns ; a n d of c o nc o mita nt me dicati o n use.  
St atistic al Met h o ds:   
I n ge ner al, descri pti ve statistics will be prese nte d f or c o nti n u o us varia bl es, a n d fre q u e nc y a n d 
perce nt a ge f or cat e g orical varia bles.  
F or t he pri mar y o bjecti ves, efficac y is defi ne d as l o weri n g of H b A [ADDRESS_664990] b o. F or t he pri mar y e n d p oi nt a nal ysis, t he pri mar y a nal ysis will utilize a mi x e d m o del re peate d meas ur es ( M M R M) a nal ysis of c o varia n ce m o del ( A N C O V A) a p pr oac h, wit h treat me nt, visit, treat me nt - b y-visit i nteracti o n a n d ra n d o mizati o n stratifica ti o n fact ors as t he fi x e d effects ter ms a n d bas eli ne H b A 1c as a c o variate o n  all a vaila ble data, i nc or p or ati n g all visits fr o m eac h patie nt at w hic h H b A 1c w as meas ure d i n t he i nte nti o n- t o-treat (I T T) a nal ysis set. All o bser ve d dat a will be a nal yz e d a n d data o btai ne d after r esc u e will n ot be e x cl u de d. I n a d diti o n, sa me a nal yses will be c o n d ucte d i n per-pr ot oc ol ( P P) a n al ysis set (if it is dee me d differ e nt fr o m t he I T T a nal ysis set).  
T he M M R M m o del is o ne a p pr oac h t o o btai n treat me nt effect esti mates i n t he p rese n ce of 
missi n g data. As se nsiti vit y a n al ys es f or missi n g d ata, t he f oll o wi n g will be perf or me d f or t he I T T a nal ysis set: 
1.  Missi n g H b A 1c d ata will be i m p ute d via m ulti ple i m p utati o n, f oll o wi n g w hic h t he 
M M R M will be re peate d o n t he c o m plete datas ets wit h  res ults c o m bi ne d acr oss c o m plete 
datasets usi n g sta n d ar d MI tec h ni q ues; H b A 1 c v al ues c ollecte d after t he start of res c ue me dicati o n will n ot be e xcl u de d.  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664991] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 0  of 7 2  V 4 ( Gl o bal)  
 2.  Missi n g H b A 1c d ata will be i m p ute d via last o bser vati o n carrie d f or war d (L O C F ), 
f oll o wi n g w hic h t he MM R M will be re peate d; H b A 1c val ues c ollecte d after t he start of 
resc ue m e dicati o n will be c o nsi der e d missi n g. 
3.  H b A 1c val ues c ollecte d after t he start of r esc ue m e dicati o n will be c o nsi dere d missi n g, 
a n d t he M M R M a nal yses will be re -perf or me d.  
If t he P P a nalysis set is differe nt fr o m t he I T T a nal ysis set, t he sa me a nal ys es as descri be d a b o ve will be c o n d u cte d i n P P a nal ysis set as well.  
T he eff ects of b e x a glifl o zi n o n t he sec o n dar y e n d p oi nts will be teste d i n a hierar c hical testi n g 
strate g y t o preser ve e x peri me nt-wi de t y pe I err or at 0. 0 5:  
1.  S u peri orit y test of t he c h a n ge i n b o d y wei g ht i n s u bjects wit h baseli ne b o d y mass i n de x 
( B MI) ≥ 2 5 k g/ m
[ADDRESS_664992] olic bl o o d pr ess ure ( S B P) o ver ti me i n s u bjects wit h 
S B P ≥  [ADDRESS_664993] of t he c h a n ge i n H b A 1c o v er ti me i n s u bjects wit h e G F R 4 5 t o 5 9 
m L/ mi n/ 1. [ADDRESS_664994] of t he c h a n ge i n H b A 1c o v er ti me i n s u bjects wit h e G F R 3 0 t o 4 4 
m L/ mi n/ 1. [ADDRESS_664995] b o gr o u p 
 
A d diti o nal effects of be x a glifl ozi n o n F P G, c ha n ges i n H b A 1c o ver ti me, pr o p orti o n of s u bjects w h o reac h a n H b A 1c < 7 %, c ha n ge i n b o d y w ei g ht o v er ti me, c ha n ge i n uri n e al b u mi n-t o-creati ni ne rati o (U A C R ) over ti me, a n d t he ge ner al safet y of be x a glifl ozi n i n s u bjects wit h T 2 D M will be a nal yz e d. N o h y p ot hesis testi n g will be c o n d ucte d a n d will n ot be a dj uste d f or m ulti plicit y.  
F or t he pri mar y efficac y e n d p oi nt, sa m ple size calc ulati o n is base d o n a t w o-si de d 
si g nifica n ce at t he 5 % le vel. Ass u mi n g 1. 0 % as t he sta n dar d d e viati o n f or differe n ce i n mea n c ha n ges fr o m baseli ne i n H b A 1c bet w ee n be x a glifl ozi n a n d place b o, a n esti mate d sa m ple size of 1 3 3 i n eac h ar m will ha ve 9 0 % p o wer t o detect a differ e nce i n mea n H b A 1c c ha n ges of 0. 4 0 % bet wee n be x a glifl ozi n a n d place b o. T o acc o u nt f or a n esti mate d dr o p o ut rate of 1 2 %, we pr o p os e ra n d o mizi n g [ADDRESS_664996] u d y a r m. 
Statistical a nal yses a n d s u m maries will be perf or me d usi n g S A S
® s oft w ar e ( S A S I nstit ute, 
Car y, N C).  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664997] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 1  of 7 2  V 4 ( Gl o bal)  
 LI S T O F A B B R E VI A TI O N S A N D D E FI NI TI O N S O F  T E R M S  
A C E  a n gi ote nsi n -c o n verti n g e nz y m e  
A D A  A merica n Di a betic Ass o ciati o n  
A E  ad verse e ve nt  
A L T  ala ni ne a mi n otra nsf eras e  
A L P  al kali ne p h os p hatase  
A N C O V A  a nal ysis of c o varia nce  
A N O V A  anal ysis of varia n ce  
A S T  as partate a mi n otra nsferas e  
A T C  A nat o mic T her a pe utic C he mical  
B MI  b o d y mass i n de x  
B U N  b l o o d urea nitr o ge n  
C F R  C o de of Fe d er al Re g ul ati o ns  
CI  c o nfi de nce i nter val 
C K  creati ni ne k i nas e 
C R F  case r e p ort f or m 
C R O  c o ntract r esearc h or ga nizati o n 
C V  car di o vas c ular  
D P P [ADDRESS_664998]  HI V  h u ma n i m m u n o deficie nc y vir us 
I C
5 0  i n hi bit or y c o nce ntrati o n 5 0 % 
I C H I nter nati o nal C o nfere nce o n Har m o nisati o n  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_664999] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 2  of 7 2  V 4 ( Gl o bal)  
 I E C I n d e pe n de nt Et hics C o m mittee  
I N D I n v esti gati o nal Ne w Dr u g  
I R A E i m me diatel y r e p orta ble a d verse e v e nt 
I R B I nstit uti o nal R e vie w B oar d  
I T T Inte nt i o n-t o-treat 
I W R S Interacti ve We b Res p o nse  S yste m  K D O QI  Ki d ne y Disease O utc o mes Q ualif y I nitiati ve  
L C -M S/ M S  li q ui d c hr o mat o gr a p h y c o u ple d wit h ta n d em mass s pectr o metr y  L D H  lactic de h y dr o ge nase  
M A C E  maj or a d vers e car di o vasc ular e ve nt  M D R D  m o dificati o n of diet i n re nal disease  Me d D R A  Me dical Dicti o nar y f or R e g ul at or y Acti vities  
MI  m y ocar dial i nfarcti o n 
M O D Y  m at urit y– o ns et dia b etes of t he y o u n g  N Y H A  Ne w Y or k Heart Ass ociati o n  
O H A  oral h y p o gl yce mia a ge nt  
P D  p har m aco d y n a mics  
P K  p har m aco ki netics  
S A E  seri o us a d vers e e v e nt  
S B P  s yst olic bl o o d press ur e  
S D  sta n dar d de viati o n  
S G L T [ADDRESS_665000] u g Dicti o nar y  
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665001] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 3  of 7 2  V 4 ( Gl o bal)  
 1 I N T R O D U C TI O N 
T y pe 2 di a betes mellit us ( T 2 D M) is o ne of t he l ea di n g ca uses of m or bi dit y a n d m ortalit y 
w orl d wi de, affecti n g a n esti mate d 3 8 7 milli o n pe o ple i n 2 0 1 4 a n d reac hi n g e pi [INVESTIGATOR_513479] o p orti o ns i n nearl y all c o u ntries i n t he w orl d.  A p pr o xi matel y 1 7 9 milli o n of t h ose aff ecte d are esti mate d t o b e  u na w are of t h eir c o n diti o n a n d o ver 8 0 % r esi de i n l o w- a n d mi d dle-i nc o me c o u ntries (I nter n ati o nal Dia betes F o u n dati o n, 2 0 1 4).  T [ADDRESS_665002] 9 0 % of all dia betes cases. Des pi[INVESTIGATOR_040] t he a vaila bilit y of se ver al classes of t her a pe utics, t he n u m ber of pe o ple wit h T 2 D M is pr ojecte d t o i ncr ease b y 5 5 % t o o v er 5 9 0 milli o n a d ults b y 2 0 3 5. 
C hr o nic gl yce mic c o ntr ol is necessar y t o pre ve nt t he micr o vasc ul ar c o m pli cati o ns of T 2 D M, 
i ncl u di n g ne p hr o p at h y. U p t o o ne-t hir d of patie nts wit h T 2 D M ha ve re n al i m pair me nt (C oll-de- T uer o et al., 2 0 1 2 ). W hile t he pr o gressi ve n at ur e of T [ADDRESS_665003] patie nts wit h T 2 D M t o re q uire m ulti ple t hera pi[INVESTIGATOR_014] t o mai ntai n n or mal gl u c ose le v els (I nz ucc hi et al., 2 0 1 2 ; T ur ner et al., 1 9 9 9 ), ma n y of t hese t hera pi[INVESTIGATOR_22920] r estricte d i n t he c o nte xt of re nal i m pair me nt (I nz ucc hi et al., 2 0 1 2). I n a d diti o n, or al h y p o gl yce mic a ge nts ( O H As) c o m m o nl y use d, s uc h as s ulf o n yl ureas, are ass ociate d wit h i ncreas e d ris ks of h y p o gl yce mia a n d wei g ht gai n p artic ularl y i n patie nts wit h re nal i m pair me nt (Ca va na u g h, 2 0 0 7 ), (I n z ucc hi et al., 2 0 1 2 ), (1 9 9 8a ). T h us, n o vel eff ecti ve t her a pi[INVESTIGATOR_014] t h at ca n be us e d saf el y i n p atie nts wit h T 2 D M a n d re nal i m pair m e nt are nee de d.  
T he re n al Na +/ gl uc os e tr a ns p ort pr otei n S G L T 2 acti vel y tr a ns p orts e xtracell ular gl uc os e i nt o 
cells usi n g t he dri vi n g e n er g y of t he tr a ns me m bra ne electr o c he mi cal p ote ntial f or s o di u m i o ns. I n di vi d uals wit h disr u pti o ns i n S L C 5 A 2, t he ge n e e n c o di n g S G L T 2, e x hi bit pr o mi ne nt gl uc os uri a i n t he a bse n ce of si g nifica nt c o- m or bi dities (Sa nter et al., 2 0 0 3 ; va n de n He u v el et al., 2 0 0 2).  T he e x creti o n of gl uc os e i n t he uri ne of dia betic s u bjects i n a m o u nts c o m para ble t o or gr eater t ha n t hat see n i n i n di vi d uals har b ori n g l oss of f u n cti o ns m utati o ns i n S L C [ADDRESS_665004] pra n dial h y per gl yce mia wit h o ut i ncreasi n g i ns uli n secreti o n, ca usi n g wei g ht gai n, or i n d uci n g h y p o gl yce mia.  Se ver al S G L T 2 i n hi bit ors ha ve bee n a p pr o v e d as a si n gle a ge nt or i n c o m bi n ati o n wit h ot her h y p o gl yce mic a ge nts  f or t he treat me nt of p atie nts wit h T 2 D M (Vi via n, 2 0 1 5 ; W hale n et al., 2 0 1 5 ).  Alt h o u g h t he effecti ve ness of S G L T 2 i n hi bit ors, meas ure d b y gl uc os uria, is re d u ce d as t h e gl o mer ular filtrati o n rate ( G F R) decr eases, t he dr u gs h a ve b ee n well t olerate d i n ge n eral a n d s u bsta ntial a m o u nt of uri nar y gl uc os e is dis p ose d i n dia betic patie nts wit h c hr o nic ki d ne y disease.  T h e effecti ve ness of S G L T 2 i n hi bit ors f or H b A 1c r e d u cti o n i n patie nts wit h m o derate re nal i m pair me nt has bee n d e m o nstrate d i n cli nical trials of ca n a glifl ozi n (Gil bert, 2 0 1 4 ; K o ha n et al., 2 0 1 4), da pa glifl ozi n (Yale et al., 2 0 1 3 ), a n d e m pa glifl ozi n ( F DA M e dical re vie w e m pa glifl ozi n, refere n ce I D: 3 4 0 2 2 5 7, p a ge 1 0 2/ 3 1 9).  Alt h o u g h t he efficac y v arie d, all S G L T 2 i n hi bit ors pr o d uce d H b A 1c re d ucti o ns i n patie nts wit h G F R bet wee n 4 5 a n d 6 0. T he cli nical efficac y i n patie nts wit h G F R bet wee n 3 0 a n d 4 5 varie d a m o n g diff ere nt S G L T 2 i n hi bit ors (Sc hee n, 2 0 1 5 ). 
I n a trial assessi n g t he car di o vasc ular h azar ds of a d mi nistrati o n of e m pa glifl ozi n ( E M P A-
R E G), dia betic patie nts wit h i ncrease d car di o v as c ular ris k were tr eate d wit h e m pa glifl ozi n or place b o i n c o m bi nati o n wit h sta n dar d of care f or a p pr o xi matel y 3 years.  T he pri mar y 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665005] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 4  of 7 2  V 4 ( Gl o bal)  
 c o m p osite o utc o me of deat h, MI, a n d str o ke ( M A C E) occ urr e d i n 1 0. 5 % of patie nts i n t he 
e m pa glifl ozi n gr o u ps a n d i n 1 2. 1 % of t he patie nts i n t he place b o gr o u p.  T h e M A C E hazar d rati o f or patie nts wit h e G F R < 6 0 was 0. 7 8 fa v ori n g e m p a glifl ozi n a n d t here was n o statisticall y si g nifica nt differ e nce b et wee n patie nts wit h n or mal a n d i m paire d re nal f u n cti o n (Zi n ma n et al., 2 0 1 5 ). 
1. 1   B e x a glifl o zi n f or t h e Tr e at m e nt of T y p e 2 Di a b et e s M ellit u s 
Be x a glifl ozi n  is a p ote nt a n d hi g hl y s pecific i n hi bit or of t he S G L T 2 wit h a n i n vitr o I C 5 0 of 
2 n M or 0. 9 n g/ m L a n d a [ADDRESS_665006] o bser va ble d os e le vel i n male rats, as w ell as si g ns of re versi ble car diac i nfla m mati o n a n d a b d o mi nal diste nsi o n at a d ose le vel of 2 0 0 m g/ k g i n m o n ke ys.  Details of t he a d v erse fi n di n gs ar e pr o vi de d i n t he I n v esti gat or’s Br oc h ure. 
1. 1. [ADDRESS_665007] u dies t o e val uate saf et y, t olera bilit y, 
p har mac o ki netics ( P K), p har mac o d y n a mics ( P D) a n d dr u g meta b olis m i n healt h y s u bjects, s u bjects wit h T 2 D M, a n d dia betic s u bjects wit h re nal i m pair me nt. Be x a glifl ozi n was well t olerate d b y patie nts wit h n or mal a n d i m paire d r e n al f u ncti o n a n d pr o d u ce d cli nicall y si g nifica nt uri n ar y gl uc os e e x creti o n ( U G E ), i n patie nts wit h n or mal re nal f u ncti o n a n d i n pati e nts wit h mil d a n d m o derate re nal i m pair me nt. Patie nts wit h re nal i m pair me nt  e x perie nce d s maller i n cr eases i n U G E  v ers us pati e nts wit h n or mal re nal f u ncti o n.  H o we ver, t he a m o u nt of gl u c os uria e x perie nce b y patie nts wit h mil d a n d m o derate re n al i m pair me nt is a ntici pate d t o pr o vi de t hera pe utic be n efit. Details of t he p har mac ol o g y, efficac y, a n d saf et y assess me nts are d escri b e d i n t he I n v esti gat or’s Br oc h ure a n d s u m marize d i n t he f oll o wi n g secti o ns.  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665008] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 5  of 7 2  V 4 ( Gl o bal)  
 2 S T U D Y O B J E C TI V E S  
2. 1  Pri m ar y O bj e cti v e  
T he pri mar y o bjecti ve is  t o deter mi ne t he efficac y of be x a glifl ozi n o n l o weri n g H b A 1 c i n 
patie nts wit h T 2 D M  a n d m o derate r e nal i m pair me nt  after 2 4 w ee ks of tr eat me nt . 
2. 2  K e y S e c o n d ar y O bj e cti v e s 
T he ke y sec o n dar y o bjecti ves are: 
• T o assess t he effect of be x a glifl ozi n o n t he c ha n ge i n b o d y wei g ht at w ee k 2 4  i n s u bjects 
wit h baseli ne B MI ≥ 2 5 k g/ m2 
• T o assess t he effect of be x a glifl ozi n o n t he c ha n ge i n s yst olic bl o o d press ur e ( S B P) at 
wee k 2 4  i n s u bjects wit h baseli ne S B P ≥ 1 3 0 m m H g 
• C ha n ge i n H b A 1c i n s u bj ects wit h e G F R 4 5 t o 5 9 m L/ mi n/ 1. 7 3 m2 at wee k 2 4  
• C ha n ge i n H b A 1c i n s u bj ects wit h e G F R 3 0 t o 4 4 m L/ mi n/ 1. [ADDRESS_665009] orat or y o bjecti ves ar e:  
• C ha n ge i n H b A 1c o v er ti me i n all s u bjects 
• Pr o p orti o n of s u bjects w h o reac h t ar get H b A 1c of <  7 % o ver ti me • C ha n ges i n fasti n g pl as ma gl u c ose ( F P G ) o ver ti me  • Pr o p orti o n of ≥ 5 % re d ucti o n of b o d y w ei g ht i n s u bjects wit h baseli ne B MI ≥ 2 5 k g/ m
2 at 
wee k 2 4  
• C ha n ge i n b o d y wei g ht i n all s u bjects o ver ti me • C ha n ges i n S B P a n d diast olic B P o ver ti me i n all s u bjects • C ha n ge i n al b u mi n uria ( uri ne al b u mi n creati ni ne rati o  or U A C R ) fr o m b aseli ne t o wee k 
2 4 i n all s u bjects a n d i n s u bjects wit h baseli ne macr oal b u mi n uria ( U A C R ≥ 3 0 0) 
 
2. [ADDRESS_665010] u d y is t he c o ntri b uti o n maj or a d vers e car di o v asc ular 
e ve nts ( M A C E) t o a n e ve nt ual meta-a nal ysis t hat is i nte n de d t o e x cl u de e x cessi ve car di o vas c ular ris ks f or s u bjects e x p ose d t o be x a glifl ozi n c o m pare d t o s u bjects e x p ose d t o place b o d uri n g t he i n vesti gati o nal p has e of be x a glifl ozi n. 
2. 4   Ot h er O bj e cti v e 
Meas ure me nt  of be x a glifl ozi n  plas ma c o nce ntrati o n as a f u ncti o n of ti me fr o m d osi n g (s parsel y sa m ple d) will be c o n d ucte d a n d will i ncl u de a p pr o xi matel y 1 4 4 s u bjects. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665011] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 6  of 7 2  V 4 ( Gl o bal)  
 [ADDRESS_665012] pr o vi de writte n i nf or me d c o nse nt a n d be willi n g a n d a ble t o a d her e t o 
t he pr ot oc ol re q uir e me nts. P ote ntial partici pa nts wit h s u b o pti mal gl yce mic c o ntr ol des pi[INVESTIGATOR_154867] a n d e x ercise or c o m bi nati o n of diet a n d e x ercise a n d treat me nt as rec o m me n de d i n l ocal g ui deli nes a n d wit h m o derate re nal i m pair me nt will e nter a scr ee ni n g peri o d of bet wee n 3 a n d 2 1 da ys . T he mai n eli gi bilit y criteria i ncl u de: 1) male or f e male s u bjects wit h T 2 D M, 2) scree ni n g H b A 1c of 7. 0 t o 1 0. 5 % (i ncl usi ve), a n d 3) esti mate gl o mer ular filtrati o n rate 
(e G F R) ≥ 3 0 t o < 6 0 m L/ mi n/ 1. 7 3 m
2 base d  o n t he ser u m creati ni ne at t he s cree ni n g visit a n d 
o ne a d diti o nal ti me p oi nt bet wee n 1 a n d 1 2 m o nt hs pri or t o scree ni n g ( ma y be o btai ne d fr o m 
a vaila ble me dical rec or ds) . T he e G F R will be cal c ulate d b y t h e m o dificati o n of diet i n re nal disease st u d y e q uati o n ( M D R D). At t he ti me of s cree ni n g, t he d os es a n d fre q ue nc y of all a nti-dia betic  me dicati o ns m ust ha ve bee n sta ble f or [ADDRESS_665013] b o r u n-i n peri o d t o all o w f or 
dia betes e d ucati o n a n d o pti mizati o n of c o m plia nce wit h diet a n d e x ercise  r ec o m me n dati o ns. Q ualifie d s u bjects will c o nti n ue t heir pre-s cree ni n g r e gi me n f or gl yce mic c o ntr ol (i ncl u di n g O H As a n d/ or i ns uli n) a n d will be i nstr ucte d t o ta ke t he r u n-i n me dicati o n o nce dail y f or [ADDRESS_665014] me nt f or a nti- dia betic m e dicati o n is n ot rec o m me n de d as it ta kes 1 2 wee ks t o esta blis h a n H b A 1c sta ble b aseli ne. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665015] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 7  of 7 2  V 4 ( Gl o bal)  
 3. 2. 3  Tr e at m e nt P eri o d  
S u bjects w h o are c o m plia nt i n ta ki n g r u n-i n me dicati o n ( missi n g n o m ore t ha n o ne d ose), 
ha ve scr ee ni n g e G F R ≥ 3 0 a n d < 6 0 m L/ mi n/ 1. 7 3 m2, a n d ha ve sta ble G F R  ( n o m ore t ha n 
2 0 % c ha n ge i n e G F R bet wee n a hist orical val ue a n d t he val ue deter mi ne d at t he scree ni n g visit V 1 ) will be eli gi ble f or ra n d o mizati o n a n d recei ve d o u ble bli n d st u d y dr u gs.  
T he treat me nt peri o d f or eac h st u d y s u bject will start at ra n d o mizati o n. A p pr o xi matel y 3 0 0 
eli gi ble s u bjects will be r a n d o mize d at t he e n d of t he r u n-i n peri o d i n a 1: 1 rati o t o recei ve o nce dail y be x a glifl ozi n ta blets f or 2 4 w ee ks . Ra n d o mizati o n will be stratifie d b y H b A 1c le vel (val ue o n s cree ni n g visit V 1 t o be 7. 0 t o 8. 5 % or 8. 6 t o 1 0. 5 %), scree ni n g a nti-dia b etic  treat me nt re gi me n (i ns uli n treate d or n ot) a n d e G F R (val ue o n scr ee ni n g visit V 1 t o be 3 0- 4 4 or 4 5- 5 9 m L/ mi n/ 1. 7 3 m
2). At least [ADDRESS_665016] wit h water i n t he m or ni n g pri or t o eati n g. A d diti o nal me dica ti o ns f or h y per gl yce mia  (see Secti o n 3. 2. 4 ) a n d f or c o ntr ol of ot her me dical c o n diti o ns will be all o wed if dee me d me dicall y n ecessar y b y t he i n vesti gat or, a n d will be rec or de d. 
T he safet y i nf or mati o n  will be dra w n fr o m r e vie w of a d vers e e ve nts ( A Es), c o nc o mita nt 
me dicati o n s, vital si g ns, electr ocar di o gr a ms ( E C Gs), a n d r es ults fr o m p h ysical e x a mi nati o ns a n d bl o o d a n d uri ne s peci me n c ollecti o ns. O n t he da y of t he cli nic visit a mi ni m u m fasti n g peri o d of [ADDRESS_665017] b e c o nfir me d pri or t o bl o o d dra w. At e v er y visit, i ncl u di n g t he p h o n e i nter vie ws, partici pa nts will be q uerie d r e gar di n g A Es a n d i nf or mati o n o n all e ve nts t hat p ote ntiall y re prese nt dia b etic ket oaci d osis ( D K A) or maj or a d verse car di o v asc ular e ve nts will be f or war de d t o a car di o vasc ular e n d p oi nt c o m mittee ( C E C) f or bli n de d a dj u dicati o n of t he e ve nt. F oll o wi n g t he e xit visit, s u bjects will be a d vise d t o see t heir pri mar y p h ysicia n t o u n der g o treat me nt t o c o ntr ol t heir dia betes a n d car di o vasc ular  c o n diti o ns. T he sc he d ule d visits a n d pr oce d ures f or eac h visit ar e pr o vi de d i n A p pe n di x 1 .  
A n assess me nt of be x a glifl ozi n  p o p ulati o n p har mac o ki netics ( P K) will als o be c o n d ucte d t o 
i ncl u de a p pr o xi matel y [ADDRESS_665018]  treat me nt  t o 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665019] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 8  of 7 2  V 4 ( Gl o bal)  
 c o ntr ol t heir dia betes.  T he d urati o n of t he o verall st u d y is esti mate d t o be a p pr o xi matel y [ADDRESS_665020] o p pe d f or f utilit y or 
o ver w hel mi n g be nefit of be x a glifl ozi n  treat me nt.  D u ri n g t h e trial, a D ata a n d Safet y M o nit ori n g B o ar d ( D S M B ) will re vie w t he u n bli n de d a g gre gate dat a peri o dicall y a n d ma y rec o m me n d a n earl y ter mi nati o n of t he trial f or s afet y r eas o ns. 
3. 2. [ADDRESS_665021] A C E B O RU N-I N PE RI O D  
D uri n g t h e p lace b o r u n-i n peri o d s u bjects will be i nstr ucte d t o deter mi ne t he S M B G dail y after f asti n g o v er ni g ht f or a mi ni m u m of 8 h.  If t he fasti n g bl o o d gl u c ose is ≥ 2 5 0 m g/ d L ( 1 3. 9 m m ol/ L) t he s u bject s h o ul d c o ntact t he cli nic a n d t he i n vesti gat or will deter mi ne w het her t he p artici pa nt s h o ul d atte m pt t o i m pr o ve diet a n d e x ercise t o mai ntai n gl yce mic c o ntr ol or if t he partici pa nt m ust disc o nti n ue fr o m t he st u d y a n d i nitiate a m ore i nt e nse p har mac ol o gical re gi me n f or gl uc ose c o ntr ol. S u bjects wit h S M B G rea di n gs ≥ 2 5 0 m g/ d L ( 1 3. 9 m m ol/ L) a n d s e ver e cli nical si g ns or s y m pt o ms of h y per gl yce mia d uri n g t he scree ni n g or r u n-i n peri o ds, i ncl u di n g w ei g ht l oss, bl urr e d visi o n, i ncrease d t hirst, i ncrease d uri nati o n, or fati g ue s h o ul d be e x cl u de d . Patie nts wit h s y m pt o matic  h y p o gl yce mia s h o ul d be wit h dra w n fr o m t he st u d y if s y m pt o ms are se vere.  
MAI N TR E A T M E N T PE RI O D  
D uri n g t h e mai n treat me nt peri o d s u bjects will be a d vise d t o c o nti n ue d ail y f asti n g S M B G meas ure me nts. I nt e nsificati o n of t he a nti-dia betic  re gi me n s h o ul d a d her e t o t he g ui deli nes descri be d i n S ecti o n 5. 2. 4  f or “Pres cri pti o n of Resc ue Me di c ati o n ”.  
S t u d y su bj ects s h o ul d c o ntact t he cli nic if a n y f asti n g S M B G is ≥ 2 7 0 m g/ d L ( 1 5 m m ol/ L) 
fr o m wee k 1 t o w ee k 6, ≥ 2 4 0 m g/ d L ( 1 3. 3 m m ol/ L) b et wee n  wee k 6 a n d  wee k 1 2, or ≥ 2 0 0 m g/ d L ( 1 1. 1 m m ol/ L) b et wee n  wee k [ADDRESS_665022] u d y visits b y t he i n vesti gat or. I n a d diti o n, h y per gl yce mia will be m o nit ore d b y f asti n g plas ma gl uc os e (F P G ) at eac h cli nical visit  e x ce pt visit V [ADDRESS_665023] be dra w n 
pri or t o t he a d mi nistrati o n of t he resc u e me dicati o n s o t hat a n H b A 1c v al ue ca n be assesse d . Starti n g metf or mi n i n patie nts wit h a n e G F R bet w ee n 3 0 -4 5 m L/ mi n ute/ 1 . 7 3 m
2 is n ot 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665024] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 1 9  of 7 2  V 4 ( Gl o bal)  
 rec o m me n de d. T he i n vesti gat or s h o ul d assess t he be nefits a n d ris ks of c o nti n ui n g metf or mi n 
treat me nt f or p atie nts w h o ha ve bee n ta ki n g metf or mi n a n d w h ose e G F R falls bel o w 4 5 m L/ mi n ute/ 1. 7 3 m
2. Metf or mi n t hera p y s h o ul d be disc o nti n ue d if the patie nt’s e G F R  f alls 
bel o w 3 0 m L/ mi n ute/ 1. [ADDRESS_665025] t he cli nic staff f or h y p o gl yce mia, defi ne d as: 1) a n y S M B G val ue < 7 0 m g/ d L ( 3. 9 m m ol/ L); or 2) a n y s y m pt o ms of h y p o gl yce mia t hat res ol ve wit h f o o d i nta ke, wit h or wit h o ut a n acc o m pa n yi n g S M B G v al ue. H y p o gl yce mia ma y als o be detecte d b y F P G val ues, meas ure d b y ce ntral la b orat or y at e v er y cli nic visit, e x ce pt V 2 , usi n g t he sa me criteri a as f or S M B G val u es.  
If rec urri n g h y p o gl yce mia (i.e., cli nicall y si g nifica nt h y p o gl yce mia o cc urri n g o n m ulti ple 
differe nt d a ys) is i de ntifie d d uri n g t he mai n treat me nt peri o d, t he d ose a n d fre q ue n c y of bac k gr o u n d ( pre- s cree ni n g) me di cal t her a p y f or dia betes s h o ul d be re d u ce d at t he discreti o n of t he i n vesti gat or. If t he s u bject is ta ki n g i ns uli n a n d O H A , t he d ose of i ns uli n s h o ul d be re d uce d first, a n d, if necessar y t o pre ve nt f urt her h y p o gl yce mia, i ns uli n s h o ul d be disc o nti n ue d bef ore oral h y p o gl yce mic a ge nts  are re d uce d. If t he s u bject is ta ki n g o nl y O H As or G L P -[ADDRESS_665026] u d y i n vesti gat ors will ma na ge bl o o d press ure a n d li pi d val ues 
acc or di n g t o acce pte d sta n dar ds of care f or t he ma na ge me nt of h y perte nsi o n a n d d ysli pi [INVESTIGATOR_30192].  
3. 2. 5. 1  R e n al F u n cti o n  
E val uati o n a n d ma na ge me nt of s u bjects wit h a n d at ris k f or ac ute ki d n e y i nj ur y ( A KI) s h o ul d 
be perf or me d d uri n g t he st u d y peri o d b ase d o n t he Ki d ne y Disease: I m pr o vi n g Gl o bal 
O utc o mes ( K DI G O) Cli nical Practice G ui deli ne i n 2 0 1 2 ( K DI G O Cli nical Practice G ui deli ne f or A KI, 2 0 1 2).  T he c lassificati o n/sta gi n g S yst e m f or A KI is des cri be d i n A p pe n di x 3 . 
If ser u m creati ni ne i ncreases s u g gesti n g a p ossi ble sta ge 1 A KI, t he i n vesti gat or s h o ul d 
c o nfir m t he i ncr ease i n s er u m cr eati ni ne wit hi n 4 8 h of lear ni n g t he r es ult a n d e nter a n A E i nt o t he C R F if t he ser u m creati ni ne d o es n ot s p o nta ne o usl y ret ur ns t o < 0. 3 m g/ d L fr o m baseli ne. T he i n vesti gat or s h o ul d e nc o ur a ge t he s u bjects t o mai ntai n h y dr ati o n a n d p urs ue a n y a d diti o nal cli nicall y rele va nt i n vesti gati o ns t o el uci date t he ca use or p ote ntial c o nse q ue nces of t he d ecli ne i n re nal f u n cti o n. St u d y dr u g a d mi nistrati o n ma y b e s us pe n de d if cli nicall y i n dicat e d u ntil t he creati ni ne val ue r et ur ns t o < 0. 3 m g/ d L fr o m b aseli ne. Ser u m creati ni ne s h o ul d be m o nit ore d base d o n t he i n vesti gat or’s j u d g me nt u ntil cr eat i ni ne ret ur ns t o baseli ne le vel, wit hi n 0. 3 m g/ d L differe n ce.  
If ser u m creati ni ne i ncreases or ot her si g ns s u g gesti n g a p ossi ble sta ge [ADDRESS_665027] o p pe d u ntil t he creati ni ne val ue ret ur ns t o < 0. 3 m g/ d L fr o m baseli ne. If p ote ntiall y life-t hreat e ni n g c o n diti o ns (i.e., ure mia, 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665028] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 0  of 7 2  V 4 ( Gl o bal)  
 p ul m o nar y e de ma, arr h yt h mia, disse mi nate d i ntra vasc ular c oa g ulati o n, h y per kale mia, 
meta b olic aci d osis  ) are prese nt occ urri n g i n t he setti n g of a p ossi ble sta ge [ADDRESS_665029] u g ma y b e rei nitiate d w h e n ser u m creati ni ne ret ur ns t o wit hi n 
0. 3 m g/ d L of t he r a n d o mizati o n val ue or if re nal f u ncti o n re mai ns 0. 5 m g/ d L a b o v e t he ra n d o mizati o n val ue b ut a n alter nati ve ca use of t h e w orse n e d re n al f u ncti o n has bee n i de ntifie d. D osi n g of st u d y dr u g will be per ma n e ntl y disc o nti n ue d if t he s u bject is t o start dial ysis or ot her re nal re place me nt t her a pi[INVESTIGATOR_014].  
T he re n al f u ncti o n m o nit ori n g pla n is s u m marize d i n Fi g ure 1. 
 
Fi g ur e  1. R e n al F u n cti o n M o nit ori n g Pl a n  
 
3. 2. 5. [ADDRESS_665030] cli nicall y -si g nifica nt aci d osis s h o ul d be d oc u me nte d; treat me nt of D K A s h o ul d be pr o vi de d w h e n a p pr o pri ate.  
If o n g oi n g s y m pt o ms or si g ns s u g gest a p ossi ble D K A, t he i n vesti gat or s h o ul d perf or m 
rele va nt la b orat or y testi n g w hile dir ecti n g a p pr o priate me dical care f or t he s u bject. If D K A is s us pecte d, re gar dless of t he bl o o d gl uc os e le vel, t he f oll o wi n g assess me nts s h o ul d be d o ne i m me diatel y: p h ysical e x a m a n d ser u m gl uc ose, bi car b o nat e, electr ol yt es, a n d ser u m ket o nes 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665031] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 1  of 7 2  V 4 ( Gl o bal)  
 meas ure d S T A T at a l ocal la b orat or y. If k et oaci d osis is li kel y, i n vesti gati o n al pr o d uct 
a d mi nistrati o n s h o ul d be disc o nti n ue d a n d i m me diate a p pr o priate me dical t hera p y, i ncl u di n g i ns uli n, s h o ul d be i nitiate d. A gl uc os e i nf usi o n ma y be pr o vi de d if necessar y t o a v oi d h y p o gl yce mia d uri n g i ns uli n t hera p y. I ns uli n treat me nt s h o ul d c o nti n ue u ntil res ol uti o n of t he ket oaci d osis a n d sta bilizati o n of t he s u bject’s cli nical c o n diti o n. I n v esti gati o nal pr o d u ct a d mi nistrati o n ma y be res u me d f oll o wi n g sta bilizati o n of t he s u bject’s c o n diti o n. I n v esti gat or s h o ul d c ollect t he data necessar y f or t he c o m pleti o n of t he D K A C R F.  
If s y m pt o ms s u g gesti ve of D K A ma y h a ve occ urr e d b ut are n ot o n g oi n g, i n vesti gat or s h o ul d 
re vie w a v aila ble dat a i n order t o c o m plete t h e D K A C R F. T he i n vesti gat or ma y als o perf or m la b orat or y ass ess me nt usi n g l ocal res o ur ces if necessar y f or cli nical care.  
3. 2. 5. 3  M aj or A d v er s e C ar di o v a s c ul ar E v e nt ( M A C E)  
A n i n de pe n de nt car di o vasc ular a dj u dicati o n c o m mittee has bee n  est a blis he d t o re vie w,  u n d er bli n d, all p ote ntial car di o vasc ular e ve nts occ urri n g d uri n g t he st u d y. T he e v e nts of i nterest i ncl u de car di o v asc ular m ortalit y, m y ocar dial i nfar cti o n, str o ke, h os pi[INVESTIGATOR_1314] o n f or ac ute c or o nar y s y n dr o mes, h os pi[INVESTIGATOR_1314] o n f or heart fail ure, ur ge nt r e vas c ularizati o n pr oce d ur es, a n d ot her p ossi ble seri o us car di o vasc ul ar e v e nts. T he a dj u dicate d e ve nts will be d oc u me nte d a n d arc hi v e d t o all o w a meta -a nal ysis t o be perf or me d at a later ti me.  
3. 2. 5. [ADDRESS_665032] be a p pr o priatel y d o c u me nte d wit hi n s o urce d oc u me ntati o n. 
• Ge nital m yc otic i nfecti o ns  
• U ri nar y tract i nfecti o ns i ncl u di n g ur os e psis a n d p yel o n e p hritis • D i uretic effects i ncl u di n g h y p o v ole mia • H y p ote nsi o n e pis o des  • He pat ot o xicit y  • M A C E  • H y p o gl yce mia  • Fa lls a n d fract ur es • M ali g na n cies  • H y p erse nsiti vit y r eacti o ns  • Aci d -base dis or d ers  • Re nal fail ure e ve nts  • A m p utati o n   
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665033] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 2  of 7 2  V 4 ( Gl o bal)  
 3. 2. 6  D A T A A N D S A F E T Y M O NI T O RI N G B O A R D ( D S M B)  
A n i n de pe n de nt D ata a n d Safet y M o nit ori n g B oar d ( D S M B) will m o nit or o verall saf et y 
i nf or mati o n d uri n g t he b e x a glifl ozi n de vel o p me nt pr o gra m. T he s afet y r e vi e w acti vit y a n d p ote ntial ris k be nefit assess me nts utilize d b y t he D S M B are d efi ne d i n its c harter.  
3. [ADDRESS_665034] u d y D e si g n  
Patie nts wit h T 2 D M ha ve i ncrease d ris k of d e vel o pi n g micr o- a n d macr o vasc ular 
c o m plicati o ns. I m pr o v e d c o ntr ol of h y per gl yce mia or bl o o d press ur e re d u ces t he ris k of dia betic c o m plicati o ns ( U K P D S  (1 9 9 8 b )). A d mi nistrati o n of be x a glifl ozi n, a p ote nt S G L T [ADDRESS_665035] u dies i n dicate t hat be x a glifl ozi n  has bee n w ell t olerate d  f or 9 6 wee ks (st u d y T H R- 1 4 4 2- C- 4 1 8). 
T he eff ect of a si n gl e d os e of be x a glifl ozi n  has bee n teste d i n patie nts wit h T 2 D M a n d 
n or mal or i m paire d r e nal f u ncti o n (st u d y T H R- 1 4 4 2- C- 4 2 4). Be x a glifl ozi n  was well t olerate d b y patie nts wit h n or mal a n d i m paire d r e n al f u ncti o n a n d pr o d uce d cli nicall y si g nifica nt U G E i n patie nts wit h n or mal re nal f u n cti o n a n d i n patie nts wit h mil d a n d m o derate r e nal i m pair me nt (Fi g ure 2 ). A d mi nistrati o n of be x a glifl ozi n pr o d uce d a mea n gl uc os uri a of 4 0 g/ d i n patie nts wit h m o derate r e n al i m pair me nt ( G F R 3 0 t o 6 0) c o m par e d t o 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665036] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 3  of 7 2  V 4 ( Gl o bal)  
 9 9. 6 g/ d i n patie nts wit h n or mal re nal f u n cti o n.  T he decr eas e d gl uc os uria is c o nsiste nt wit h a 
re d uce d re n al filtrati o n rate. H o we ver, a n i m pr o ve me nt i n gl yce mic c o ntr ol ca n be pr e dicte d b y t he U G E of nearl y [ADDRESS_665037] u g was als o w ell t olerate d  b y patie nts wit h se vere r e nal  i m pair me nt b ut pr o d uce d a U G E  le vel t hat is u nli kel y t o pr o vi de t hera pe utic b e nefit. T hes e fi n di n gs pr o vi de rati o n ale f or e x a mi ni n g t he cli nical effi cac y i n patie nts wit h T 2 D M a n d m o derate r e nal i m pair me nt .  
 
 
Fi g ur e  2.  Gl u c o s uri a i n p ati e nt s wit h n or m al a n d i m p air e d r e n al f u n cti o n 
 
SA F E T Y CO N SI D E R A TI O N  
Be x a glifl ozi n is pri maril y meta b oli ze d t o i nacti ve gl uc ur o ni d es b y p hase II meta b olis m a n d 
is cleare d t hr o u g h re n al or fecal e x creti o n. P har mac o ki netic ( P K) para meters of be x a glifl ozi n a n d its pri nci pal meta b olites were d eter mi ne d i n p atie nts wit h T 2 D M a n d r e nal i m pair me nt. Re d uce d clear a nce d u e t o  re nal i m pair me nt w as ass ociate d wit h a 3 4 % or 5 4 % hi g h er s yste mic e x p os ure i n s u bjects wit h G F R bet wee n 3 0 a n d 6 0 m L/ mi n/ 1. 7 3 m
2 or bel o w 
3 0 m L/ mi n/ 1. 7 3 m2, res pecti vel y. T he half -life w as e xte n de d fr o m 6. 5 h ( G R F > 9 0) t o 7. 7 h 
( G F R < 3 0) wit h n o acc u m ulati o n of be x a glifl ozi n or its maj or meta b olites.  N o n -cli nical a n d cli nical st u dies ha ve de m o nstrate d hi g h m ulti ples of safet y mar gi ns f or be x a glifl ozi n ta blet, [ADDRESS_665038] u d y h as de m o nstrate d t hat 1 0 0 m g of b e x a glifl ozi n a d mi nistere d i n a n i m me diate release f or m ulati o n di d n ot pr ol o n g t he Q T i nter val or pr o d uce a d vers e c h a n ges i n a n y ot her par a meters meas ur e d b y E C G. 
3. 3. 3  R ati o n a l e f or t h e D o s e S el e cti o n 
Be x a glifl ozi n pr o d uces a d ose- de pe n d e nt, sat ura bl e i ncrease i n U G E i n healt h y v ol u nteers 
a n d dia betic s u bjects. N ear - ma xi mal U G E is pr o d uce d b y 2 0 m g of be x a glifl ozi n, w het her 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665039] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 4  of 7 2  V 4 ( Gl o bal)  
 deli vere d as a n i m me diate release or a n e xte n de d r elea se f or m ulati o n. A si n gle d ose of 2 0 m g 
pr o d uces a si g nifica nt re d ucti o n i n fasti n g plas ma gl uc ose ( F P G) a n d a m o dest di uretic effect. P o p ulati o n p har mac o d y na mic m o deli n g has i n dicate d t hat be x a glifl ozi n d oses of 2 0 m g w o ul d r es ult i n 9 0 % of t he ma xi mal U G E , res pecti vel y. I n a l o n g-t er m treat me nt st u d y, dail y a d mi nistrati o n of 2 0 m g be x a glifl ozi n was f o u n d t o re d uce H b A 1c b y 0. 7 9 % c o m par e d t o place b o at w ee k 2 4. T he treat me nt be n efit was o bser ve d t o i m pr o ve t o 1. 0 2 % at wee k [ADDRESS_665040] olic bl o o d press ure were als o o bser ve d f oll o wi n g 9 6 w ee ks of treat me nt. I n a d diti o n, A Es, partic ularl y t h ose i n v ol vi n g U TI a n d ge nital m yc otic i nfecti o ns ( G MI), wer e f o u n d t o be si milar bet wee n place b o a n d acti ve a ge nt c o h orts . T o e v al uat e t he saf et y a n d efficac y of be x a glifl ozi n f or t he tr eat me nt of patie nts wit h T [ADDRESS_665041] u d y s u bjects. F or d etails of t he sc he d ule a n d nat ur e of t he i n vesti gati o ns, see t h e Sc he d ule of E ve nts i n A p pe n di x 1 . 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665042] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 5  of 7 2  V 4 ( Gl o bal)  
 [ADDRESS_665043] u d y p o p ulati o n will i ncl u de: 
1.  Me n or n o n- pr e g na nt w o me n ≥ [ADDRESS_665044] u d y t o a v oi d a n y p ossi ble pr e g na n c y. 
Fe males w h o ar e s ur gicall y sterile ( h yst erect o m y, o o p h orect o m y) or p ost m e n o pa usal 
(a bse nce of me ns es greater t ha n 1 2 m o nt hs a n d a ge > 4 5 years) are eli gi ble if t he y test 
ne gati ve o n t he u ri ne pre g na n c y test. 
2.  S u bjects wit h a dia g n osis of T 2 D M wit h a n H b A 1 c bet wee n 7. 0 a n d 1 0. 5 % (i ncl usi ve) at 
t he ti me of scree ni n g. 
3.  S u bjects w h o are tr eat me nt naï ve or ar e treate d wit h a sta ble re gi me n of a nti -dia betic 
me dicati o ns  t hat d o n ot pr o vi de a de q u ate gl yce mi c c o ntr ol w he n c o m bi ne d wit h diet a n d e x ercise. At t he ti me of s cree ni n g, t he d os es a n d fre q ue nc y of all a nti- dia b etic me dicati o ns m ust ha ve b ee n sta ble f or 8 wee ks.  
4.  S u bjects w h o ha ve a n esti mate d gl o mer ul ar filtrati o n rate ( e G F R) ≥ 3 0 a n d 
< 6 0 m L/ mi n/ 1. 7 3 m
2 at 2 ti me p oi nts: scree ni n g ( V 1), a n d 1 a d diti o nal ti me p oi nt 
bet wee n 1 a n d 1 2 m o nt hs of scree ni n g ( m ost rece nt hist orical val ue ma y be o btai ne d fr o m a vaila ble me dical r ec or ds). T h e e G F R  will be calc ul ate d b y t he M D R D e q uati o n (see A p p e n di x 4 ) 
5.  S u bjects w h o ha ve a b o d y mass i n de x ( B MI) ≤ 4 5 k g/ m
2 (i ncl usi ve) 
6.  S u bjects w h o ta ke sta ble d oses of me dicati o ns f or h y perte nsi o n or h y perli pi [INVESTIGATOR_30192] f or at 
least 3 0 da ys pri or t o ra n d o mizati o n (if a p plica ble) 
7.  S u bjects w h o ha ve sta ble e G F R  bet w ee n t he m ost rece nt hist oric v al ue a n d da y of 
scree ni n g ( n o m ore t ha n 2 0 % c ha n ge i n e G F R bet wee n t he m ost rece nt  hist orical val ue a n d t he val ue d eter mi ne d at t he scree ni n g visit V 1 ). 
 
4. [ADDRESS_665045] u d y. 
1.  D ia g n osis of t y p e 1 dia betes mellit us or mat urit y– o nset dia betes of t he y o u n g ( M O D Y) 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665046] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 6  of 7 2  V 4 ( Gl o bal)  
 2.  He m o gl o bi n o pat h y t hat affects H b A 1c meas ure me nt  
3.  F re q u e nt s y m pt o matic h y p o gl yce mia ( gr eater t h a n o ne e pis o de per wee k o n a vera ge) 4.  Ge nit o uri nar y tract i nfecti o n wit hi n [ADDRESS_665047] or y of ≥ [ADDRESS_665048] 6 m o nt hs 
5.  Ca ncer, acti ve or i n r e missi o n f or < 3 yea rs ( N o n-mela n o ma s ki n ca ncer or basal cell 
carci n o ma or carci n o ma i n sit u of t he cer vi x will n ot be gr o u n ds f or e x cl usi o n) 
6.  Hist or y of alc o h ol or illicit dr u g a b us e i n t he past 2 years 
7.  E vi de nce of a b n or mal li v er f u ncti o n tests (t otal bilir u bi n or al kali ne p h os p h atase > 1. 5 x 
u p per li mit of n or mal ( U L N) wit h t he e x ce pti o n of is olate d Gil bert's s y n dr o me); or ala ni ne a mi n otra nsf eras e ( A L T) or as partat e a mi n otra nsfer ase ( A S T) > 2. [ADDRESS_665049] or y of MI, str o ke or h os pi[INVESTIGATOR_1314] o n f or heart f ail ure, or h os pi[INVESTIGATOR_1314] o n f or u nsta ble 
a n gi n a i n t he pri or 3 m o nt hs 
9.  E vi de nce of N Y H A class I V heart fail ure at scr ee ni n g or r a n d o mizati o n  1 0.  C urre ntl y or wit hi n 3 m o nt hs of ta ki n g a n S G L T 2 i n hi bit or fr o m scree ni n g (A p pe n di x 5 ) [ADDRESS_665050]'s a p pr o priate partici pati o n i n t his st u d y or o bsc ure t he eff ects of treat me nt  
[ADDRESS_665051] me nt t hera p y ( p erit o neal or h e m o dial ysis) or w h o 
ha ve u n der g o ne r e nal tra ns pla ntati o n 
1 4.  C orrecte d s er u m cal ci u m <  8 m g/ d L ( A p pe n di x 4 ) at scree ni n g ( V 1) or ra n d o mizati o n 
( V 3) 
1 5.  U nc o ntr olle d h y pert e nsi o n (s yst olic bl o o d press ur e > [ADDRESS_665052] olic bl o o d press ure 
> 1 1 0) 
[ADDRESS_665053] u g d uri n g t he r u n-i n peri o d 1 9.  Fasti n g bl o o d gl uc os e val ue d uri n g t he r u n-i n peri o d ≥ 2 5 0 m g/ d L  ( 1 3. 9 m m ol/ L) 
ass ociate d wit h  se vere cli nical si g ns or s y m pt o ms of h y p er gl yce mia  
2 0.  A n y e pis o de of s y m pt o matic h y p o gl yce mia d uri n g t he r u n-i n peri o d i n w hic h s y m pt o ms 
are se v ere  
2 1.  S u bjects w h o are u n a ble t o rea d a n d write i n t heir nati ve la n g ua ge 2 2.  S u bjects w h o are u n a ble t o c o m pre he n d a n d willi n g t o pr o vi de writte n i nf or me d c o nse nt 
i n acc or d a nce wit h i nstit uti o nal a n d re g ulat or y g ui deli nes 
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665054] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 7  of 7 2  V 4 ( Gl o bal)  
 [ADDRESS_665055] u g pr o d u cts e x hi bit a great er t ha n 7 5 % releas e of dr u g s u bsta nce b y [ADDRESS_665056] u gs will be us e d f or or al a d mi nistrati o n: 
• Be x a glifl ozi n ta blets, 2 0 m g: ta blets c o ntai ni n g 2 0 m g of be x a glifl ozi n  
• Be x a glifl ozi n ta blets, place b o: ta blets c o ntai ni n g n o be x a glifl ozi n   
5. [ADDRESS_665057] b o, s h o ul d be ta ke n i n t he m or ni n g pri or t o eati n g or 
dri n ki n g. T he t a blets  s h o ul d be ta ke n wit h 2 5 0 m L of water.  
5. 2. 2  B a c k gr o u n d Or al H y p o gl y c e mi c A g e nt s ( O H A s)  
S u bjects will c o nti n ue O H As t hat wer e pres cri be d pri or t o scree ni n g. T h e d ose, fre q u e nc y, 
a n d ti me of a d mi nistrati o n of t hese me dicati o ns s h o ul d re mai n sta ble t hr o u g h o ut t he st u d y u nless t he i n vesti gat or d ee ms a dj ust me nt necessar y f or t he me dical well - bei n g of t he s u bject. C ha n ges t o t he d os e or fr e q ue nc y of oral a nti -dia b etic me dicati o ns will be r ec or de d i n t he c o nc o mita nt me dicati o ns l o g.  
5. 2. [ADDRESS_665058] me nt ( d ecrease or i ncreas e) necessar y f or t h e me dical w ell- bei n g of t he s u bject. C ha n ges t o t h e d ose, fr e q ue nc y, or ti me of a d mi nistrati o n of i n s uli n will be rec or de d i n t he c o nc o mita nt me dicati o ns l o g.  
5. 2. [ADDRESS_665059]. A re vi e w of diet a n d e x ercise c o u nseli n g is s u g geste d pri or t o pres cri pti o n of resc ue me di cati o n i n t he a bse nce of s pecific me dical i n dicati o ns f or resc u e me dicati o n. Resc ue me dicati o n is s u g geste d if:  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665060] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 8  of 7 2  V 4 ( Gl o bal)  
 1.  m ore t ha n 3 c o nsec uti ve, dail y, f asti n g S M B G meas ures are ≥ 2 7 0 m g/ d L ( 1 5 m m ol/ L) 
fr o m wee k 1 t o w ee k 6, ≥ 2 4 0 m g/ d L ( 1 3. 3 m m ol/ L) fr o m wee k 6 t o wee k 1 2, or 
≥ 2 0 0 m g/ d L ( 1 1. 1 m m ol/ L) fr o m wee k 1 2 t o wee k 2 4, or 
2. fasti n g S M B G val ues are ≥ 2 5 0 m g/ d L ( 1 3. 9 m m ol/ L,), ass o ciate d wit h cli nical si g ns or 
s y m pt o ms of h y per gl yce mia (e. g. wei g ht l oss, bl urre d visi o n, i ncrease d t hirst, or i ncreas e d uri nati o n, or f ati g ue), a n d t he si g ns or s y m pt o ms are s e ver e. 
 A me dicati o n gi ve n t o treat h y p er gl yce mia will be c o nsi dere d a res c ue t her a p y f or h y per gl yce mia o nl y if it is c o nti n ue d f or [ADDRESS_665061] u g i n t hat class as a c o nse q u e nce of bei n g r a n d o mize d t o recei v e be x a glifl ozi n. Starti n g metf or mi n i n patie nts wit h a n e G F R bet w ee n 3 0 - 4 5 m L/ mi n ute/ 1. 7 3 m
2 is n ot rec o m me nde d. T h e i n vesti gat or s h o ul d assess t he be nefits a n d 
ris ks of c o nti n ui n g metf or mi n treat me nt f or p atie nts w h o ha ve bee n ta ki n g metf or mi n a n d w h ose e G F R falls bel o w 4 5 m L/ mi n ute/ 1. 7 3 m
2. Metf or mi n treat me nt s h o ul d be 
disc o nti n ue d if the patie nt’s e G F R  f alls bel o w 3 0 m L/ mi n ute/ 1. [ADDRESS_665062] u d y s u bjects will be i nstr ucte d t o self -a d mi nister ta blets o nce dail y i n t he m or ni n g pri or t o eati n g or dri n ki n g; t he me di cati o n s h o ul d be ta ke n wit h w ater. T here will be n o c ha n ge of d ose d uri n g t he treat me nt peri o d. 
O n t he da y of eac h s c he d ule d cli nic visit, s u bjects m ust fast f or a mi ni m u m of 8 h o urs pri or 
t o t he c ollecti o n of bl o o d sa m ples. D uri n g t he fasti n g peri o d, o nl y w ater will be per mitte d. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665063] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 2 9  of 7 2  V 4 ( Gl o bal)  
 5. [ADDRESS_665064] u d y will be c o n d ucte d at i n vesti gati ve sites i n m ulti ple c o u ntries a n d will li kel y i n v ol ve 
varia ble n u m bers of s u bjects at eac h site. E nr oll me nt will be o n a c o m petiti ve basis b ut eac h site will be ca p pe d at 3 0 ra n d o mize d s u bjects per site. Acti vati o n of i n vesti gati o nal sites i n eac h c o u ntr y will be ce ntrall y c o ntr olle d b y a ce ntrall y ma n a ge d I nteracti ve We b Res p o nse S yste m (I W R S). 
Eli gi ble s u bjects w h o c o m plete t he r u n -i n peri o d a n d meet all st u d y i n cl usi o n/e x cl usi o n 
re q uire me nts will be r a n d o mize d t o recei ve i n vesti gati o nal pr o d uct.  T h e treat me nt peri o d f or eac h st u d y s u bject will start at ra n d o mizati o n. A p pr o xi matel y 3 0 0 eli gi ble patie nts will be ra n d o mize d at t he e n d of t he r u n-i n peri o d i n a 1: 1 rati o t o recei ve o nce d ail y be x a glifl ozi n ta blets f or 2 4 wee ks. Ra n d o mizati o n will be stratifie d b y H b A 1c le v el ( 7. 0 t o 8. 5 % or 8. 6 t o 1 0. 5 %), scr ee ni n g a nti-di a betic  treat me nt re gi me n (i ns uli n treate d or n ot) a n d scree ni n g e G F R ( 3 0 - 4 4 or 4 5- 5 9 m L/ mi n/ 1. 7 3 m
2). 
S u bject ra n d o mizati o n will be deacti vate d f or all sites w he n t he pla n ne d n u m ber of s u bjects is met.  H o we ver, if a p ote ntial s u bject is  i n r u n-i n peri o d alrea d y a n d wis h es t o c o nti n ue wit h t he st u d y, t he s u bject will be all o we d t o c o nti n ue a n d, if eli gi ble, t o be ra n d o mize d.  
5. [ADDRESS_665065]’s c o n diti o n, t he i n vesti gat or 
will c o ntact t he I W R S t o o btai n t he treat me nt assi g n me nt.  If u n bli n di n g occ urs f or a n y reas o n, t he ti me a n d reas o n f or brea ki n g t he bli n d will be rec or d e d o n t he case re p ort f or m ( C R F) a n d t he s p o ns or m ust be n otifie d wit hi n [ADDRESS_665066] u dies are c o m plete d  a n d a meta-a n al ysis t o assess car di o v asc ular ris k is c o n d ucte d. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665067] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 0  of 7 2  V 4 ( Gl o bal)  
 5. [ADDRESS_665068] u d y i n vesti gat ors will ma na ge gl uc ose, bl o o d press ure, li pi d le vels, 
a n d a ne mia acc or di n g t o l ocal or re gi o n al sta n dar d of car e g ui da nce d oc u m e n ts f or t he ma na ge me nt of T 2 D M a n d ot her c o m or bi dit y or disease as iss ue d b y t he r ele va nt pr ofessi o nal b o dies ( e. g. A D A, t he Nati o nal Ki d n e y F o u n dati o n, et c.). S u bjects s h o ul d be pr o vi de d access t o all a d diti o nal t hera pi[INVESTIGATOR_014] a n d i nter ve nti o ns d uri n g t he c o urs e of t he st u d y if t hese ar e cli nicall y i n dicate d a n d a p pr o v e d b y l ocal c o m pete nt a ut h orities. 
S u bjects will be all o we d t o ta ke me dicati o ns or m e dici nal s u p ple me nts prescri be d t o ma na ge 
n o n- dia betic me dical c o n diti o ns d uri n g t he st u d y. A n y c o nc urre nt me dicati o n or s u p ple me ntal treat me nt of ot her, n o n- dia b etes me dical c o n diti o ns s h o ul d be c o nti n ue d at a sta ble d ose a n d fre q ue n c y f or t he e ntire st u d y d ur ati o n u nless t here is cli nical reas o n t o c ha n ge t he d os e or fre q u e nc y.  
Bl o o d press ur e me dicati o ns s h o ul d n ot be altere d d uri n g t he s cree ni n g p eri o d a n d t he first [ADDRESS_665069] u d y. A nti -dia betic t her a pi[INVESTIGATOR_513480] d t o s u bjects f or t he p ur p ose of tr eati n g h y per gl yce mia f or m ore t ha n 2 wee ks will be c o nsi der e d res c ue me di cati o ns ( Secti o n 5. 2. 4 Resc ue Me dicati o n s f or H y per gl yce mia).  
S u bjects ma y r ecei ve a n y me dicati o ns f or A Es t hat are necessar y i n t he i n vesti gat ors’ 
j u d g me nts. A n y me dicati o n prescri be d t o a s u bject after e nr oll me nt a n d pri or t o ra n d o mizati o n, i ncl u di n g c o ntrace pti ves, m ust be rec or d e d i n t he C R F. T he me dicati o n na me, d ose, fr e q ue n c y, r o ute of a d mi nistrati o n, date(s) of a d mi nistrati o n a n d reas o n f or a d mi nistrati o n m ust be rec or de d. T his d oc u me nt ati o n s h o ul d c o nti n ue t hr o u g h t he tr eat me nt a n d f oll o w u p peri o ds.  
5. [ADDRESS_665070] u g, 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665071] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 1  of 7 2  V 4 ( Gl o bal)  
 w hic he ver is l o n ger. N o s u bject s hall ha ve bee n tr eate d wit h a n S G L T [ADDRESS_665072] 1 5 0 mi n/ wee k of m o derate acti vit y is a d vise d b y t he A merica n Di a betes Ass o ciati o n (A merica n Dia b etes, 2 0 1 4 ). Alter n ati vel y, l ocal g ui deli nes ma y b e use d.  
5. [ADDRESS_665073] acc or di n g t o ra n d o mizati o n assi g n me nt made i n t he I nter acti ve We b Res p o nse S yste m  (I W R S). D uri n g t he treat me nt peri o d, s u bjects will be pr o vi de d wit h a ne w b ottle e ver y [ADDRESS_665074] b o. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665075] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 2  of 7 2  V 4 ( Gl o bal)  
 T he la bel attac he d t o eac h r u n -i n kit will c o ntai n t he pr ot oc ol n u m ber, pr o d uct i de ntificati o n, 
l ot n u m ber, s u bject n u m ber, st ora ge c o n diti o n, t he s p o ns or’s na me a n d a d dr ess, e x pi[INVESTIGATOR_1313] o n  date, t he i n vesti gati o nal dr u g ca uti o n state me nt, a n d a n y ot h er r e q uire d st u d y dr u g i nf or mati o n. 
5. 9. [ADDRESS_665076] u d y kit will c o ntai n s o me or all of t he f oll o wi n g i nf or m ati o n: 
t he kit n u m ber, pr ot oc ol n u m ber, pr o d uct i de ntificati o n, bli n de d batc h n u m ber, a desi g n ate d s pace f or s u bject n u m ber, st ora ge c o n diti o ns, s p o ns or’s na me, ma n ufact ur er's na m e a n d a d dress, i n vesti gat or’s n a me, e x pi[INVESTIGATOR_1313] o n  date, t he i n vesti gati o nal dr u g ca uti o n state me nt,  a n d a n y ot h er r e q uire d st u d y dr u g i nf or mati o n. 
5. [ADDRESS_665077] ore d i n a sec ure area wit h li mite d access at c o ntr olle d r o o m te m peratur es of 1 5° C t o 3 0° C ( 5 9° F t o 8 6° F) u ntil rea d y f or dis p e nsi n g t o st u d y s u bjects. T he s p o ns or will n otif y t he sites of t he pr ocess f or ret ur ni n g u n use d dr u g. 
5. [ADDRESS_665078] da y of d osi n g ( V 8 visit ), t he st u d y dr u g b ottle a n d a n y r e mai ni n g ta bl ets will be c ollecte d fr o m t he patie nt a n d st ore d at t he site u ntil t he cl ose - o ut visit. All  u n use d dr u g m ust be ret ur ne d t o a s p o ns or-desi g nat e d de p ot after t he s p o ns or or its desi g nee verifies dr u g acc o u nti n g . 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665079] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 3  of 7 2 V 4 ( Gl o bal)  
 [ADDRESS_665080] be i nf or me d t hat 
he/s he is free t o wit h dra w fr o m t he st u d y at a n y ti me. He or s he will recei ve all i nf or mati o n 
t hat is re q uire d b y nati o n al re g ulati o ns a n d G o o d Cli nical Practice ( G C P)  g ui deli nes.  
T he i nf or me d c o ns e nt d o c u me nt m ust be si g ne d a n d date d; o ne c o p y will b e gi v e n t o t he 
patie nt, a n d t he i n vesti gat or will retai n a c o p y as part of t he cli nical st u d y r ec or ds. T he i n vesti gat or will n ot u n d erta ke a n y i n vesti gati o n s pecificall y r e q uire d f or t he cli nical st u d y u ntil writte n c o nse nt has bee n o btai ne d. T h e ter ms of t he c o nse nt a n d w he n it was o btai ne d m ust als o be d oc u me nte d. 
6. 3   S cr e e ni n g f or I/ E Crit eri a  
At t he i nitial scree ni n g, t he i n vesti gat or s h o ul d re vie w t he i ncl usi o n a n d e x cl usi o n criteria base d o n t he i nf or mati o n c ollecte d at t he s cree ni n g visit. He or s he s h o ul d e val uate a n y c ha n ge t o stat us affecti n g c o nf or ma n ce t o i ncl usi o n a n d e x cl usi o n criteria at s u bse q ue nt visits pri or t o ra n d o mizati o n. At ra n d o mizati o n, t he i n vesti gat or s h o ul d c o nfir m t he r u n-i n dr u g c o m plia nce.  
6. [ADDRESS_665081] or y  
T he f oll o wi n g i nf or mati o n will be c ollecte d at t he scree ni n g visit:  
6. 4. [ADDRESS_665082] or y, i n cl u di n g dates of dia g n oses a n d pr oce d ur es a n d 
w het her t he c o n diti o n is o n g oi n g, if a p plica ble. 
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665083] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 4  of 7 2  V 4 ( Gl o bal)  
 6. 4. [ADDRESS_665084] or y of all me dicati o ns use d t o treat dia betes ( t o be rec or de d i n t he c o nc o mita nt 
me dicati o n f or m), i ncl u di n g start dat e, d urati o n of use, a n d st o p date, if a p plica ble. 
2.  Hist or y of c o m plicati o ns d ue t o dia betes, i ncl u di n g ne p hr o pat h y, r eti n o pat h y, 
ne ur o pat h y, n o n-tr a u matic a m p utati o ns, a n d dia betic ket oaci d osis, i ncl u di n g date of 
dia g n osis 
3.  Fre q u e nc y of h y p o gl yce mic e ve nts ( per wee k) t h at are s y m pt o matic or re q uire assista nce.   
6. 4. [ADDRESS_665085] or y  
1.  C hr o nic ki d ne y disease sta ge, base d o n K O QI C K D cla ssificati o n a n d d urati o n 
(A p pe n di x 3 ) 
2.  C urre ntl y recei vi n g er yt hr o p oiesis -sti m ulati n g a ge nt ( E S A) f or a n e mia a n d ti me of 
starti n g E S A 
3.  Hist or y of b o n e diseas e 
4.  Hist or y of dis or d ers of calci u m a n d p h os p h or us meta b olis m or h y p er parat h yr oi dis m 5.  Hist or y of n e ur o pat h y 6.  Hist or y of car di o v asc ular disease i ncl u di n g pres e n ce of a n gi n a, c o n gesti ve heart f ail ure 
(i ncl u di n g N Y H A cl assificati o n), k n o w n at her oscl er otic car di o vasc ular disease, pri or MI, tra nsie nt isc he mic attac k or str o ke, a n d pri or car diac or peri p her al re-v asc ul arizati o n pr oce d ur es. T he hist or y s h o ul d i ncl u de t he date of dia g n osis a n d t he c urr e nt stat us of dia g n osis (r es ol ve d or o n g oi n g). 
 
6. 4. [ADDRESS_665086] u d y. I n a d diti o n, all s u bjects are e nc o ur a ge d t o c o ns u me e n o u g h li q ui d t o mai ntai n a de q uate h y drati o n. 
6. 6   P h y si c al E x a mi n ati o n  
A c o m plete p h ysical e x a mi nati o n will be perf or m e d b y t h e i n vesti gat or at t he ti me p oi nts i n dicate d i n t he Sc he d ule of E ve nts (A p pe n di x 1 ). T he e x a mi nati o n will i ncl u de a ge neral assess me nt of all b o d y s yste ms i ncl u di n g t he s ki n, hea d, e yes, ears, n ose, t hr oat, nec k, heart, l u n gs, a b d o me n, l y m p h n o des, a n d e xtre mities. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665087] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 5  of 7 2  V 4 ( Gl o bal)  
 6. 7   A b br e vi at e d P h y si c al E x a mi n ati o n  
A n a b bre viat e d p h ysical e x a mi nati o n will i ncl u de meas ure me nt of  h ei g ht at scree ni n g  V 1  
o nl y a n d a ge neral assess me nt of t he s ki n, heart, l u n gs a n d a b d o me n. T he i n vesti gat or will perf or m a b b re viat e d p h ysical e x a mi nati o ns at t he ti me p oi nts i n dicate d i n t he Sc he d ule of E ve nts ( A p pe n di x 1 ), u nless cli nicall y i n dicate d. 
6. [ADDRESS_665088] u d y d ur ati o n. 
6. 9   Vit al Si g n s  
Vital si g ns will be meas ure d at t he ti me p oi nts i n dicate d i n t he Sc he d ule of E ve nts ( A p pe n di x 1 ) a n d will i ncl u de s u pi [INVESTIGATOR_050], sitti n g a n d sta n di n g B P meas ure me nts, a n d heart rate. O nl y t he B P meas ur e d i n t he sitti n g p ositi o n will be use d t o deter mi ne eli gi bilit y.  
De vices desi g n e d t o meas ure B P fr o m t he fi n ger or wrist ma y n ot be use d. T he left ar m a n d 
sa me c uff sizes s h o ul d be use d f or eac h meas ure m e nt at all visits. If t he left ar m ca n n ot be use d at t he scr ee ni n g visit or d uri n g t he st u d y f or B P meas ur e me nts, t he reas o n s h o ul d b e d oc u me nte d, a n d t he ri g ht ar m s h o ul d be use d f or B P meas ur e me nts f or all s u bse q ue nt visits. 
At eac h visit, B P meas ur e me nts will be o btai ne d usi n g a cali brate d s p h y g m o ma n o meter 
w hile t he s u bject is i n sitti n g, s u pi [INVESTIGATOR_050], a n d sta n di n g p ositi o ns. A si n gle hear t rate meas ure me nt s h o ul d be ta ke n j ust pri or t o t he B P e val uati o n i n t he sitti n g, s u pi [INVESTIGATOR_050], a n d sta n di n g p ositi o ns.  
All rea di n gs ar e t o be e nt ere d i nt o t he s o urce d oc u me nt a n d C R F f or all s u bjects. T he date 
a n d ti me of B P meas ure me nts s h o ul d be ca pt ure d i n t he s o urce d oc u m e nt a n d C R F. B P will be assesse d first i n t he sitti n g p ositi o n. Sitti n g B P a n d heart rate will be meas ure d after t he s u bject has been sitti n g f or at least [ADDRESS_665089] will sta n d. Sta n di n g B P a n d h eart r ate will be meas ure d after 2 mi n  of sta n di n g. F or sta n di n g B P meas ure me nts, t he ar m s h o ul d be s u p p orte d a n d e xte n de d s uc h t hat t he c uff is at heart le v el.  
6. 1 0   El e ctr o c ar di o gr a p h y  
A 1 2 -lea d el ectr o car di o gra m ( E C G) will be c o n d u cte d at t he ti me p oi nts i n dicate d i n t he Sc he d ule of E ve nts i n A p pe n di x [ADDRESS_665090]. E C G para meters meas ur e d 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665091] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 6  of 7 2  V 4 ( Gl o bal)  
 will be t he R R i nter val, P R i nter val, Q R S d urati o n, a n d Q T i nter val. E ac h E C G s h o ul d als o 
be assesse d b y t he i n v esti gat or f or si g ns of isc h e mia, cli nicall y si g nifica nt h y p ertr o p h y, a n d cli nicall y si g nifica nt T -w a ve a b n or m alities or arr h yt h mia.  
It is t he i n vesti gat or’s res p o nsi bilit y t o re vi e w t he res ults of t he E C G as t he y bec o me 
a vaila ble. F or eac h a b n or mal E C G res ult, t he i n vesti gat or s hall as certai n if t he o bser vati o n re pres e nts a cli nicall y si g nifica nt c ha n ge fr o m t he scree ni n g E C G f or t hat i n di vi d ual s u bject.  T his deter mi nati o n  d oes n ot necess aril y n ee d t o be ma d e t he first ti me a n a b n or mal res ult is o bser ve d. T he i n vesti gat or m a y re p eat t he E C G t o verif y t he ori gi n al res ult. If t he E C G res ult is deter mi ne d t o be a cli nicall y si g nifi ca nt a n d a b n or mal c ha n ge fr o m baseli ne f or t hat s u bject, it is c o nsi dere d t o reflect a n A E.  
6. [ADDRESS_665092] para meters  ar e liste d i n Ta ble 1.  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665093] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 7  of 7 2  V 4 ( Gl o bal)  
 T a bl e  [ADDRESS_665094] N a me    Bl o o d or Uri ne V ol. 
( m L) S hi p me nt  
He m at ol o g y  2 ( bl o o d)  A m bie nt  
- He mat ocrit ( Hct)  - He m o gl o bi n ( H g b)  
- Mea n c or p usc ular he m o gl o bi n 
( M C H) 
- Mea n c or p usc ular he m o gl o bi n 
c o nce ntrati o n ( M C H C)  
- Platelet c o u nt  - Mea n c or p usc ular  v ol u me 
( M C V) 
- Re d cell distri b uti o n wi dt h 
( R D W) 
- Re d bl o o d cell ( R B C) c o u nt  
- W hite bl o o d cell ( W B C) 
c o u nt wit h differe ntial   
   
Ser u m C he mistr y a n d Electr ol ytes    1 0 (ser u m)  A m bie nt  
- Al b u mi n ( A L B)  
- Ala ni ne a mi n otra nsferase ( A L T)  
- As partate a mi n otra nsferase ( A S T)  
- Bl o o d urea nitr o ge n ( B U N)  
- Gl uc ose  
- Bicar b o nate ( H C O 3) 
- Creati ni ne  - C hl ori de ( Cl)  
- T otal pr otei n  - Calci u m ( Ca)  
- Ma g nesi u m  
- P h os p h or us  
- P otassi u m ( K)  - S o di u m ( Na)  - T otal bilir u bi n  
- Direct bilir u bi n  - Uric aci d   
   
Gl yce mic C o ntr ol      A m bie nt  
- Fasti n g plas ma gl uc ose ( F P G)  
- He m o gl o bi n A 1c ( H b A 1c)    2 ( plas ma)  
2 ( bl o o d)    
Ser u m Li pi [INVESTIGATOR_805]    6 (ser u m)  A m bie nt  
- T otal c h olester ol ( T C)  - Hi g h -de nsit y li p o pr otei n 
c h olester ol ( H D L -C)  
- Tri gl yceri des ( T G)  - L o w -de nsit y li p o pr otei n 
c h olester ol ( L D L -C), 
calc ulate d  
- L D L -C, direct (if a p plica ble)   
     
Uri n al ysis    1 0 ( uri ne)  A m bie nt  
- A p peara nce  - Bilir u bi n  - C ol or  
- Gl uc ose  
- Ket o nes  
- Micr osc o pic e xa mi nati o n of 
se di me nt  - Nitrite  
- Occ ult bl o o d  - p H  
- Pr otei n  
- S pecific gra vit y  - Ur o bili n o ge n  
- Le u k oc yte esterase   
   
Uri n ar y Al b u mi n Assess me nt  
- U A C R   2 ( uri ne ) A m bie nt  
Uri ne pre g n a nc y test ( W O C B P)    2 ( uri ne)  L ocal 
P o p ul ati o n P K S a m pli n g  
- B e xa glifl ozi n plas ma le vel    2 ( plas ma)  Fr oze n  
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665095] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 8  of 7 2  V 4 ( Gl o bal)  
 6. [ADDRESS_665096] ret ur n as s o o n as ca n be arra n ge d ( wit hi n 1 wee k) t o pr o vi de a s peci me n after pr o p er f asti n g.  
L D L -C will be calc ul ate d b y  t he Frie d e wal d e q u ati o n. If tri gl yceri des are > 4 0 0 m g/ d L, t he 
calc ulate d L D L-C val ue is i n vali d b y t his e q uati o n a n d will be set as missi n g. Dir ect L D L -C will be deter mi ne d i n s u b jects w h ose tri gl yceri des are >3 5 0 m g/ d L at scree ni n g visit. All s u bse q ue nt L D L -C of t hese s u bjects will be deter mi ne d b y t he sa m e direct L D L -C meas ure me nts o nl y.  
A n i n vesti gat or ca n p erf or m a d diti o nal la b orat or y testi n g t o dia g n ose or t o f oll o w u p a n 
a d verse e ve nt pr o gressi o n or res ol uti o n. Cli nical sa m ples s h o ul d be a nal yz e d i n a l ocal la b orat or y if a fast t ur nar o u n d ti me is necessar y t o deter mi ne treat me nt pla n.  
6. 1 1. 1. 2  Uri n al y si s  
Uri ne sa m ples will be c ollecte d r o uti nel y at desi g n ate d cli nic visits fr o m a clea n cat c h sa m ple. Uri nal ysis will be perf or me d at t he ti me p oi nts i n dicate d i n t he sc he d ule of e v e nts (A p pe n d i x 1 a n d A p pe n di x 2 ). I n v esti gat or or staff s h o ul d d oc u me nt if pre- me n o pa usal fe male s u bjects are me nstr uati n g a n d n ot e it i n t he s o urce d oc u m e nts si nce he mat uria is li kel y t o be i de ntifie d o n di pstic k uri nal ysis. 
Uri ne sa m ples will be tra ns p orte d t o t he ce ntr al la b orat or y f or uri nal ysis. Micr osc o p y will be 
c o n d ucte d if t he s u bject has a p ositi ve res ult o n t he le u k oc yte esteras e or nitrite di pstic k tests t o clarif y t he si g nifica n ce of t he fi n di n g. Res ults of gl uc ose m eas ur e me nt i n t he uri nal ysis m ust be s u p presse d fr o m t he la b orat or y r e p orts s o t he s p o ns or, i n vesti gat ors, st u d y c o or di nat ors, p har macists, st u d y s u bjects, a n d t he C E C me m bers will re mai n bli n de d t o t he d osi n g assi g n me nt. 
I n a d diti o n, stri ps t o assess le u k oc yt e ester ase a n d nitrite b ut n ot gl uc ose will be pr o vi de d f or 
i m me diate assess me nt at t he cli nical sites. If m ore t ha n traces of p ositi ve res ults are s h o w n i n t he le u k oc yte esterase a n d / or nitrite testi n g, a uri n e c ult ure s h o ul d be p erf or me d i n a desi g n ate d la b orat or y r e gar dless of p atie nt re p orte d si g ns or s y m pt o ms. Res ults of t he uri nal ysis a n d p ossi ble uri ne c ult ure will be d oc u m e nte d i n t he C R Fs. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665097] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 3 9  of 7 2  V 4 ( Gl o bal)  
 6. 1 1. 1. 3  R e n al f u n cti o n t e sti n g  
Ser u m creati ni ne will be meas ure d as part of t he s er u m c he mi str y at t he s c he d ule d cli nical 
visits.  U A C R will be deter mi ne d at  ti me p oi nts s pecifie d i n t he sc h e d ule of la borat or y tests (A p pe n di x 2 ).  
At t he scree ni n g a n d ra n d o mizati o n visits ( V 1 a n d V 3), se r u m sa m ples m ust be s u b mitte d t o 
t he ce ntral la b orat or y f or ser u m creati ni ne testi n g. T he ser u m creati ni ne v al ue deter mi ne d  at t he scree ni n g visit b y t he ce ntral la b orat or y will b e t he val ue f or assessi n g eli gi bilit y, assi g ni n g strat u m at r a n d o mizati o n, a n d t he ce ntral la b ser u m creati ni ne val ue deter mi ne d at t he ra n d o mizati o n ( V 3) will be t he baseli ne val ue f or t he data a nal yses.  
D uri n g t h e st u d y p eri o d, if a ra pi d t ur nar o u n d ti me is necessar y f or cli nical assess me nt of a 
p ote ntial ki d ne y i nj ur y, t esti n g fr o m l ocal la b or at ories s h o ul d be use d. 
6. [ADDRESS_665098] d ose (r o uti ne 1). A n ot her [ADDRESS_665099]- d ose (r o uti ne 2). T he s a m pli n g ti me s h o ul d ta ke i nt o c o nsi derati o n t he st u d y s u bject a vaila bilit y a n d ca n b e o n a n y of t he da ys d uri n g t h e wee k of t he s pecifie d cli nical vi sits. T he d ose d oes n ot nee d t o be ta ke n at t he cli nic h o we v er t he pr ecise d osi n g ti me a n d sa m ple dra w ti me m ust be rec or de d  i n t he C R F. 
T w o m L ( 2 m L) of w h ol e ve n o us bl o o d will be c ollecte d fr o m a p eri p heral vei n. Sa m ples 
will be place d i n t u bes c o ntai ni n g K
2E D T A, st ore d o n ice, a n d ce ntrif u ge d u n der 
refri gerati o n f or at least t e n mi n utes at 3, [ADDRESS_665100] ore d at or bel o w - 2 0o C u ntil a nal ysis.  
Plas ma c o nce ntr ati o ns of be x a glifl ozi n will be deter mi ne d b y a vali dat e d L C -M S/ M S met h o d. A p pr o xi matel y [ADDRESS_665101] a n d rec or d  t h e fi n di n gs i n t he C R F . 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665102] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 0  of 7 2  V 4 ( Gl o bal)  
 6. [ADDRESS_665103] t hat da y.  
6. 1 6  A d v er s e E v e nt s A s s e s s m e nt s  
6. 1 6. 1  D efi niti o n of A d v er s e E v e nt s  
A d verse e v e nt ( A E ): A n y u nt o war d me dical o cc urre nce i n a s u bject a d mi nistere d a 
p har mace utical pr o d uct t hat d oes n ot necess aril y ha ve a ca usal r elati o ns hi p wit h t he treat me nt.  
A n A E ca n t h eref ore b e a n y u nf a v ora bl e a n d u ni nt e n de d si g n (i ncl u di n g a n a b n or mal 
la b orat or y fi n di n g), s y m pt o m, or disease te m p orall y ass ociat e d wit h t he use of a me dici n al pr o d uct, w het her or n ot it is c o nsi dere d r elate d t o t he me dici nal pr o d uct us e. 
Seri o us a d verse e ve nt ( S A E): A seri o us a d verse e ve nt (e x perie n ce) or reacti o n is a n y 
u nt o war d me dical o cc urr e nce t hat at a n y d ose:  
• res ults i n deat h,  
• is life-t hreate ni n g, ( N O T E: T he ter m "life -t hreat e ni n g" i n t his c o nte xt refers t o a n e ve nt 
i n w hic h t he s u bject was at ris k of deat h at t he ti m e of t he e v e nt; it d oes n ot refer t o a n e ve nt w hic h h y p ot heticall y mi g ht h a ve ca use d deat h if it were m ore s e ver e.)  
• re q uires i n patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_1314] o n,  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665104] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 1  of 7 2  V 4 ( Gl o bal)  
 • res ults i n persiste nt or si g nifica nt disa bilit y/i n ca pacit y, 
• is a c o n ge nital a n o mal y/ birt h defect, or  • is a me dicall y i m p ortant e ve nt or r eacti o n. Me dical a n d scie ntific j u d g me nt s h o ul d be 
e x ercise d i n deci di n g w h et her ot her sit uati o ns s h o ul d be c o nsi dere d s eri o us s uc h as i m p orta nt me dical e ve nts t hat mi g ht n ot be i m me diatel y life-t hreate ni n g or res ult i n deat h or h os pi[INVESTIGATOR_1314] o n b ut ma y je o p ar dize t he s u bject or ma y re q uir e i nter ve nti o n t o pre ve nt o ne of t he ot her o ut c o mes liste d i n t he defi niti o n a b o ve. T hese s h o ul d als o us uall y be c o nsi dere d seri o us. E x a m ples of s uc h e ve nts are i nte nsi ve treat me nt i n a n e mer ge n c y r o o m or at h o me f or aller gic br o n c h os pas m; bl o o d d yscrasias or c o n v ulsi o ns t hat d o n ot res ult i n h os pi[INVESTIGATOR_1314] o n; or de vel o p me nt of dr u g d e pe n de n c y or dr u g a b use.  
 A d verse R e acti o n: A n a d verse r eacti o n mea ns a n y a d v erse e ve nt ca use d b y a dr u g. A d verse reacti o ns are a s u bs et of all s us pecte d a d v erse e ve nts i n w hic h t here is a r eas o n t o c o ncl u de t hat t he dr u g ca us e d t he e ve nt. 
U ne x pecte d A d verse Dr u g Re acti o n ( U A D R): A n a d verse reacti o n, t he nat ure or se verit y 
of w hic h is n ot c o nsiste nt wit h t he a p plica ble pr o d uct i nf or mati o n (e. g., I n v esti gat or’s Br oc h ure f or a n u n a p pr o ve d i n vesti gati o nal me di ci nal pr o d uct). 
Seri o us a n d U ne x pecte d S us pecte d A d verse R e acti o n ( S U S A R): T h e s p o ns or m ust re p ort 
i n a n I N D safet y re p ort a n y s us pecte d a d v erse reacti o n t o st u d y treat me nt (i.e., i ncl u di n g acti ve c o m parat ors) t h at is b ot h seri o us a n d u ne x pecte d ( 2 1 C F R 3 1 2. 3 2(c)( 1)(i)). Bef ore s u b mitti n g a n I N D safet y re p ort, t he s p o ns or n ee ds t o e ns ure t hat t he e v e nt meets all t hree of t he defi niti o ns:  
• S us pecte d a d verse r eacti o n  
• Seri o us  • U ne x pecte d   Se verit y: A Es will be gr a de d o n a 3- p oi nt scale a n d re p orte d as i n dicate d i n t he C R F. T he i nte nsit y of a n a d vers e e x perie nce is defi ne d as f oll o ws: 
1 = Mil d: e ve nt is me dicall y si g nifica nt b ut pr o d u ces n o disr u pti o n t o dail y acti vit y; 2 = M o derat e: e ve nt is me dicall y si g nifi ca nt a n d r e d uces or aff ects n or mal dail y acti vit y;  3 = Se ver e: e ve nt is me di call y si g nifica nt a n d r es ults i n i na bilit y t o w or k or perf or m n or mal dail y acti vit y.  
 I n vesti g ati o n al Pr o d uct C a us alit y: A n assi g n me nt ma de b y t h e i n vesti ga t or base d o n t he circ u msta nces of t he e v e nt a n d its a nal ysis. Cases wit h ca usal rel ati o ns hi p classifie d as p ossi ble, pr o ba ble or defi nite are defi ne d as relate d. Cases wit h ca usal r elati o ns hi p cate g orize d as n ot li kel y or u nrelate d are d efi ne d as n ot relate d.  Relati o ns hi p of a n A E t o d osi n g will be assess e d as f oll o ws: 
Defi nite:  T he e ve nt r es p o n ds t o wit h dra wal of t he i n vesti gati o nal pr o d u ct ( dec halle n ge), a n d rec urs wit h rec halle n ge b y a d mi nistrati o n of t he i n vesti gati o nal pr o d uct.  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665105] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 2  of 7 2  V 4 ( Gl o bal)  
 Pr o b a ble:  T h ere is a reas o na ble ca us al relati o ns hi p bet wee n t he i n vesti gati o nal pr o d uct 
a n d t he A E. T he e ve nt r es p o n ds t o dec halle n ge. R ec halle n ge is n ot re q uire d. P ossi ble:  T here is a r eas o na ble ca us al relati o ns hi p bet wee n t he i n v esti gati o nal pr o d uct a n d t he A E. D ec halle n ge is lac ki n g or d ec h alle n ge res p o nse is u nclear.  N ot Li kel y : T here is a te m p oral relati o ns hi p t o i n vesti gati o nal pr o d u ct a d mi nistrati o n, b ut t here is n ot a reas o na ble ca usal r elati o ns hi p bet wee n t he i n vesti gati o nal pr o d uct a n d t he e ve nt.  U nrel ate d : T h ere is n ot a te m p oral or ca usal r elati o ns hi p t o i n vesti gati o nal pr o d uct a d mi nistrati o n.  
 
6. [ADDRESS_665106] u d y. T o a v oi d bias i n c ollecti n g i nf or m ati o n a b o ut A Es, t he i n vesti gat or s h o ul d as k s u bjects t he f oll o wi n g q u esti o n: " H o w ha ve y o u felt si nce y o u wer e last c hec ke d?" All A Es (seri o us a n d n o n-seri o us) re p orte d b y t he s u bject m ust be rec or d e d o n t he s o urce d o c u me nts a n d C R Fs pr o vi de d b y t h e s p o ns or. 
It is t he i n vesti gat ors r es p o nsi bilit y t o re vi e w t he res ults of all la b orat or y t ests as t he y 
bec o me a v aila ble. F or eac h a b n or mal la b orat or y t est res ult t he i n vesti gat or nee ds t o ascertai n if t his is a cli nicall y si g nifica nt c ha n ge fr o m b aseli ne f or t hat i n di vi d ual s u bject (t his deter mi nati o n, h o we ver, d oes n ot necess aril y n ee d t o be ma de t he first ti me a n a b n or mal val ue is o bser ve d. T h e i n vesti gat or m a y re p eat t he la b orat or y test or r e q uest a d diti o nal tests t o verif y t he res ults of t h e ori gi n al la b orat or y t ests). If t he la b orat or y val u e is deter mi ne d t o be a cli nicall y si g nifica nt a n d a b n or mal c h a n ge fr o m baseli ne f or t hat s u bject, t his is c o nsi dere d a la b orat or y A E.  
H y p o gl yce mia is defi ne d as a n y F P G or S M B G val ue < 7 0 m g/ d L a n d d oc u me nte d as 
descri be d i n Secti o n 6 . 1 6. 1 1. 
A n y i ncreas e i n li ver f u n cti o n tests ( A S T, A L T, or bilir u bi n) gr eater t ha n [ADDRESS_665107] be n otifie d 
i m me diatel y b y tele p h o n e, e mail, or f a x of a n y i m me diatel y re p orta ble A Es (I R A E) acc or di n g t o t he pr oce d ure o utli ne d bel o w. S pecial atte nti o n s h o ul d be pai d t o rec or di n g h os pi[INVESTIGATOR_1314] o n a n d c o nc o mita nt me dicati o ns.  
6. [ADDRESS_665108] (i ncl u di n g 
la b orat or y a b n or malities) s h o ul d be re p orte d t o t he s p o ns or wit hi n 3 w or ki n g da ys. T h e C R F A E f or m s h o ul d be c o m plete d a n d se nt t o t he s p o ns or. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665109] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 3  of 7 2  V 4 ( Gl o bal)  
 S u bjects e x perie nci n g a n S A E s h o ul d be f oll o we d cli nicall y u ntil t heir healt h has ret ur ne d t o 
baseli ne stat us or n o f urt her i m pr o ve me nt i n c o n diti o n ca n be e x pecte d wit h f urt her car e. It is e x pecte d t hat t he i n vesti gat or will pr o v i de or arra n ge a p pr o pri ate s u p p orti ve care f or t he s u bject. 
6. [ADDRESS_665110] u d y, i n a ma n ner s uc h t hat ris k of fail ure is mi ni mize d. Acce pta ble birt h c o ntr ol met h o ds i ncl u de, b ut are n ot li mite d t o, oral c o ntrace pti ves, i ntr a uteri ne de vices, De p o -Pr o vera
®, N or pla nt®, h or m o nal c o ntr ace pti ve i m pla nts, bilateral t u bal li gati o n, part ner 
wit h vasect o m y, c o n d o m or dia p hra g m pl us c o ntr ace pti ve s p o n ge, f oa m, or jell y, a n d a bsti ne nce.  
 
Bef ore e nr olli n g W O C B P i n t his cli nical trial, i n vesti gat ors m ust re vi e w g ui deli nes a b o ut 
st u d y partici p ati o n f or W O C B P. T he t o pi[INVESTIGATOR_1102] s h o ul d ge n erall y i ncl u de: 
• Ge ner al i nf or mati o n  
• I nf or me d c o ns e nt f or m • Pre g n a nc y pr e ve nti o n i nf or mati o n • Dr u g i nteracti o ns wit h h or m o nal c o ntrace pti ves. • C o ntrace pti ves i n c urre nt use. • G ui deli nes f or t he f oll o w- u p of a r e p orte d pre g na n c y.  Pri or t o st u d y e nr oll me nt, W O C B P m ust be a d vise d of t he i m p orta nce of a v oi di n g pre g n a nc y d uri n g trial p artici pati o n a n d t he p ote ntial ris k fact ors f or a n u ni nte nti o nal pre g na nc y. T he s u bject m ust si g n a n i nf or me d c o nse nt f or m stati n g t he a b o ve- me nti o ne d ris k fact ors a n d t h at t he c o nse q ue n ces w ere disc usse d wit h her. 
D uri n g t h e st u d y, all W O C B P s h o ul d be i nstr ucte d t o c o ntact t h e i n vesti gat or i m me diatel y if 
t he y s us pect t he y mi g ht b e pre g na nt (e. g. misse d or late me nstr ual c ycle). 
If a s u bject or i n vesti gat or s us pects t hat t he s u bject ma y b e pre g n a nt pri or t o i n vesti gati o nal 
pr o d uct a d mi nistrati o n, t he i n vesti gati o nal pr o d uct a d m i nistrati o n m ust be wit h hel d u ntil t he res ults of ser u m pr e g na n c y t ests are a vaila ble. If t he pre g na n c y is c o nfir m e d, t he s u bject m ust n ot recei ve t h e i n vesti gati o nal pr o d uct a n d m ust n ot be e nr olle d or r e mai n i n t he st u d y. If pre g na nc y is s us pecte d w hile t he s u bject is recei vi n g st u d y treat me nt, t he i n vesti gati o nal pr o d uct m ust be wit h hel d i m me diatel y u ntil t he res ult of t he pre g na n c y test is k n o w n. If pre g na nc y is c o nfir me d, t he i n vesti gati o nal pr o d uct will be per ma ne ntl y disc o nti n ue d a n d t he s u bject will be wit h dra w n fr o m t he trial. ( E x ce pti o ns t o st u d y dis c o nti n uati o n ma y be c o nsi dere d f or life -t hr eat e ni n g c o n diti o ns o nl y aft er c o ns ultati o ns wit h a s p o ns or Me dical M o nit or or desi g n ate d pers o n nel.) T he i n vesti gat or m ust n otif y t he Me dical M o nit or wit hi n [ADDRESS_665111] rec or d t he e ve nt o n t he Pr e g na nc y S ur veilla nce F or m a n d f or w ar d it t o 
s p o ns or’s cli nical or desi g nat e d pers o n n el. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665112] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 4  of 7 2  V 4 ( Gl o bal)  
 Pr ot oc ol re q uire d pr o ce d ures f or st u d y disc o nti n u ati o n a n d f oll o w- u p m ust be perf or me d o n 
t he s u bject u nless c o ntrai n dicate d b y pre g n a nc y (e. g., x-ra y st u dies). Ot h er a p pr o priate pre g na nc y f oll o w - u p pr o ce d ures s h o ul d b e c o nsi d ere d if i n dicate d. I n a d diti o n, t he i n vesti gat or m ust re p ort t o t he s p o ns or, o n t he a p pr o priate Pre g n a nc y S ur veilla nce F or m, a n y f oll o w- u p i nf or mati o n re gar di n g t h e c o urs e of t he pre g na nc y, i n cl u di n g p eri natal a n d ne o natal o utc o me. I nfa nts will be f oll o we d f or a mi ni m u m of si x m o nt hs. 
6. [ADDRESS_665113]’s treat me nt is re q uire d f or cli nical car e a n d safet y. T h e E mer ge n c y C o de Brea k m o d ule i n t he I W R S is use d f or s uc h sit uati o ns. T he i n vesti gat or m ust c o nfir m t he i nte nti o n t o u n bli n d t he s u bject’s treat me nt t o o btai n t he d ose i nf or mati o n i n I W R S. U p o n c o m pleti o n of t he u n bli n di n g, t he s yste m will se n d a n al ert t o desi g nate d st u d y tea m me m bers t hat a n u n bli n di n g e v e nt has occ urr e d. D oc u m e ntati o n of brea ki n g t he bli n d s h o ul d be rec or de d i n t he s u bject’s me dical rec or d wit h t he date a n d ti me t he bli n d was br o ke n, a n d t he na mes of t h e pers o n nel re q uesti n g a n d a ut h orizi n g u n bli n di n g. T h e treat me nt assi g n me nt will c o nti n ue t o be wit h hel d fr o m t he C E C me m bers u ntil all p hase [ADDRESS_665114]’s c o n diti o n. T he i n vesti gat or s h o ul d c o nti n ue t o re p ort a n y si g nifica nt f oll o w- u p i nf or mati o n t o t he s p o ns or u ntil t he e ve nt has bee n r es ol ve d.  
A n y n e w S A Es re p orte d b y t he s u bject t o t he i n vesti gat or t hat occ ur after t he last sc he d ule d 
c o ntact, a n d are d eter mi n e d b y t h e i n vesti gat or t o be reas o n a bl y ass ociat e d wit h t he use of t he i n vesti gati o nal pr o d u ct, s h o ul d be re p orte d t o t he s p o ns or or desi g nat e d pers o n nel. T his ma y i ncl u d e S A Es t hat ar e ca pt ur e d o n f oll o w- u p t ele p h o ne c o nt act or at a n y ot her ti me p oi nt after t he d efi ne d st u d y peri o d (i.e., u p t o last sc he d ule d c o ntact). T h e i n vesti gat or s h o ul d f oll o w S A Es i de ntifie d after t he last sc h e d ule d c o ntact u ntil t he e ve nts are res ol ve d, or t he s u bject is l ost t o f oll o w- u p. T he i n vesti gat or s h o ul d c o nti n ue t o re p ort a n y si g nifica nt f oll o w-
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665115] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 5  of 7 2  V 4 ( Gl o bal)  
 u p i nf or mati o n t o t he s p o ns or u ntil t he e ve nt has b ee n res ol v e d. T his st u d y re q uires t hat 
s u bjects be acti vel y m o nit ore d f or S A Es f or at least [ADDRESS_665116] I nf e cti o n s ( U TI s)  
E ve nts p ote ntiall y r e pres e nti n g U TIs, i ncl u di n g c ystitis, uret hritis, p yel o n e p hritis, or 
ur ose psis, s h o ul d be car ef ull y e v al uate d a n d d o c u me ntati o n of si g ns, s y m pt o ms, c ult ure res ults f or i nfecti o us a ge nt, a n d treat me nt s h o ul d be u n derta k e n w he n a p pr o priate.  
T he i n vesti gat or s h o ul d q uer y t he s u bject at e ver y visit f or s y m pt o ms t hat ma y b e relat e d t o a 
U TI a n d, if a p pr o priate, d oc u me nt t hese e v e nts as s y m pt o matic U TI i n t he C R F u nless a n alter nati ve dia g n osis is prese nt. I n a d diti o n, a clea n catc h uri ne s a m ple will be o btai ne d a n d a uri nal ysis will be perf or me d  o n t hat sa m ple at e v er y cli nical visit  e x ce pt t he visit V 2 . A p ositi ve uri nal ysis will be defi ne d as o ne wit h det ecta ble le u k o c yt e esteras e a n d/ or nitrites. If t he s u bject re p orts s y m pt o ms c o nsiste nt wit h a U TI or t he uri nal ysis at t he cli nical site is p ositi ve, a uri ne c ult ure will be perf or me d at t he ce ntral la b orat or y. A p ositi ve uri ne c ult ure will be defi ne d as o n e wit h 1 0
5 C F U of a n y s p ecies. T he i n vesti gat or ma y als o perf or m a 
uri ne c ult ure usi n g l ocal res o urces if necessar y f or cli nical car e.  
6. 1 6. 9  G e nit al M y c oti c I nf e cti o n s ( G MI s)  
T he i n vesti gat or will q uer y t he s u bj ects f or si g ns or s y m pt o ms t hat ma y re prese nt a G MI at 
all cli nic visits. G MIs will be dia g n os e d base d o n s y m pt o ms a n d, if a p pr o pri ate, p h ysi cal e x a m a n d la b orat or y fi n di n gs. I n vesti gat ors m ust e x cl u de t he p ossi bilit y of se x uall y tra ns mitte d i nfecti o ns bef ore dia g n osi n g G MI. Dia g n osis of G MIs m ust be d oc u me nte d i n t he C R F. 
6. 1 6. 1 0  H e p at ot o xi cit y  
If plas ma A S T a n d/ or A L T c o nce ntr ati o ns > 3 x U L N ar e detecte d, t he i n vesti gat or will 
rec or d i n t he s o urce d o c u me nts t he date c orres p o n di n g t o t he date of t he la b orat or y a b n or malit y; t he t y pe, fre q ue nc y, a n d d os e of a n y c o nc urr e nt me dicati o ns or s u p ple me nts ta ke n b y t he s u bject wit hi n t he 1 4 da ys of t he detecte d a b n or malit y; a n d a n y s y m pt o ms or c ha n ge i n p h ysical e x a m t hat ha ve occ urr e d si nce t he pri or assess me nt. T h e i n vesti gat or s h o ul d perf or m a d diti o nal la b orat or y a n d i ma gi n g tests t o atte m pt t o esta blis h t he ca use of t he A S T a n d A L T ele v ati o ns, i ncl u di n g r uli n g o ut a n y p ot e ntial c o ntri b uti o n fr o m b o ne or m uscle eti ol o gies.  
A n y cli nicall y si g nifica nt i ncreas e i n he patic e nz y mes a n d s pecificall y a n y A L T or A S T > [ADDRESS_665117] e ver y 9 6 h o ur ( 4 da ys) u ntil A L T a n d A S T ret ur n t o < 2. [ADDRESS_665118] o p pe d a n d t he e ve nt s h o ul d be re p orte d as a la b or at or y A E wit hi n t he C R F if t he e nz y me ele vati o n is c o nfir me d or w orse ni n g.  
He pat ot o xicit y will be d ia g n os e d a n d e ntere d as a n A E s h o ul d a n y of t he f oll o wi n g occ ur: 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665119] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 6  of 7 2  V 4 ( Gl o bal)  
 • A L T or A S T > 8 x U L N;  
• A L T or A S T > 3 x U L N a n d t otal bilir u bi n > 2 x U L N or I N R > 1. 5 • A L T or A S T > 3 x U L N wit h t he a p pear a nce of f ati g ue, na us ea, v o miti n g, ri g ht u p per 
q ua dra nt pai n or t e n der n ess, fe ver, ras h, a n d/ or e osi n o p hilia ( > 5 %).  
 I n t he e ve nt of h e pat ot o xicit y, i n vesti gati o nal pr o d uct s h o ul d be per ma n e ntl y disc o nti n ue d. T he i n vesti gat or is e nc o ura ge d t o c o ns ult wit h t he Me dical M o nit or re gar di n g dia g n ostic e val uati o n f or t he h e patic e nz y me el e vati o ns. C o ns ultati o n wit h a he pat ol o gist ma y als o be a p pr o priate i n s o me circ u msta nces.  
6. [ADDRESS_665120] will be e x pecte d t o rec or d i n t he gl yce mic c o ntr ol diar y t he f oll o wi n g 
i nf or mati o n f or eac h h y p o gl yce mic e ve nt: 
1.  Si g ns a n d s y m pt o ms attri b ute d t o h y p o gl yce mia a n d t he ti me a n d date o n w hic h t he y 
occ urr e d  
2.  S M B G rea di n g at t he ti me of t he si g ns a n d s y m pt o ms attri b ute d t o h y p o gl yce mia  
3.  Ti me ela pse d fr o m t he m ost rece nt meal t o t he o nset of si g ns a n d s y m pt o ms 4.  T y pe of treat me nt use d ( e. g., j uice, cr ac k ers) f or t he si g ns a n d s y m pt o ms a n d w het her 
assista nce was re q uir e d fr o m a n ot her pers o n t o a d mi nister t he treat me nt  
5.  S M B G rea di n g [ADDRESS_665121] u d y visit, t he i n vesti gat or is e x pecte d t o re vie w t he gl uc o m eter a n d gl yce mic 
c o ntr ol diar y wit h partic ular atte nti o n t o a n y S M B G val ue < 7 0 m g/ d L a n d a n y rec or de d si g ns or s y m pt o ms p ote ntiall y relate d t o h y p o gl yce mia. I n a d diti o n, t he i n vesti gat or s h o ul d q uer y t he s u bject wit h re gar d t o t he occ urre nce of si g ns a n d s y m pt o ms p ote ntiall y relate d t o h y p o gl yce mia e ve n if n o ne are rec or de d i n t he diar y.  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665122] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 7  of 7 2  V 4 ( Gl o bal)  
 I n t he e ve nt of a bl o o d gl uc ose val ue < 7 0 m g/ d L or si g ns a n d s y m pt o ms p ote ntiall y rel ate d 
t o h y p o gl yce mia, t h e i n vesti gat or s h o ul d c o m plet e t he s u p ple me ntal C R F t hat  will i ncl u de data fr o m t he gl yce mic c o ntr ol diar y a n d acti o n ite ms t o re d uce f ut ure h y p o gl yce mia e pis o des.  
H y p o gl yce mia e v e nts will be rec or de d i n t he h y p o gl yce mia l o g u n d er 5 cat e g ories:  
1.  Se vere h y p o gl yce mia: a n e ve nt re q uiri n g assista nce b y a n ot her p ers o n t o acti vel y 
a d mi nister car b o h y drate, gl uca g o n, or ot her res uscitati ve acti o ns. T hese e pis o des ma y 
be ass ociate d wit h s uffici e nt  ne ur o gl yc o pe ni a t o i n d uce seiz ure or c o ma. Plas ma gl uc ose m eas ur e me nts ma y n ot b e a vaila bl e d uri n g s uc h a n e ve nt, b ut ne ur ol o gical rec o ver y attri b uta ble t o t he rest orati o n of pl as ma gl uc ose t o n or mal is c o nsi dere d s ufficie nt e vi de n ce t hat t he e ve nt w as i nd uce d b y a l o w plas ma gl uc ose c o nce ntrati o n. 
All s uc h e ve nts s h o ul d be rec or de d as S A Es i n t he C R F. 
2.  D oc u me nte d s y m pt o matic h y p o gl yce mia: a n e ve nt d uri n g w hic h t y pi[INVESTIGATOR_2855] s y m pt o ms of 
h y p o gl yce mia ar e acc o m pa nie d b y a meas ure d plas ma gl uc os e c o nce ntrati o n < 7 0 m g/ d L ( 3. 9 m m ol/ L).  
3.  As y m pt o matic h y p o gl yce mia: a n e ve nt n ot acc o m pa nie d b y t y pi [INVESTIGATOR_2855] s y m pt o ms of 
h y p o gl yce mia b ut wit h a meas ure d bl o o d gl uc ose c o nce ntr ati o n < 7 0 m g/ d L ( 3. 9 m m ol/ L).  
4.  Pr o ba ble s y m pt o matic h y p o gl yce mia: a n e v e nt d uri n g w hic h s y m pt o ms of 
h y p o gl yce mia ar e n ot acc o m pa nie d b y a bl o o d gl uc ose deter mi nati o n b ut t hat is pres u ma bl y ca us e d b y a bl o o d gl uc ose c o nce ntrati o n < 7 0 m g/ d L ( 3. 9 m m ol/ L). 
5.  Relati ve h y p o gl yce mia: A n e ve nt d uri n g w hic h t h e pers o n wit h dia bet es re p orts a n y 
of t he t y pi[INVESTIGATOR_2855] s y m pt o ms of h y p o gl yce mia, a n d i nt er prets t h ose as i n dicati ve of 
h y p o gl yce mia, b ut wit h a meas ure d plas ma gl u c os e c o nce ntrati o n > 7 0 m g/ d L 
( 3. 9 m m ol/ L).  
 
W hile eac h e ve nt meeti n g t he criteria a b o ve will be e nter e d i nt o t he h y p o gl yce mia l o g, o nl y critical h y p o gl yce mia, d o c u me nte d s y m pt o matic h y p o gl yce mia, as y m pt o matic h y p o gl yce mia, a n d pr o b a ble h y p o gl yce mia will be e ntere d as A Es.  
I n t he e ve nt of as y m pt o m atic h y p o gl yce mia, t he i n vesti gat or s h o ul d r e vie w t he si g ns a n d 
s y m pt o ms of h y p o gl yce mia wit h t he s u bject t o elicit a c o m plete descri pti o n a n d s h o ul d re vie w pr o p er gl uc o met er tec h ni q ue t o e ns ur e t hat t he l o w gl uc os e val ue is n ot d ue t o i m pr o per use of t he gl u c o meter. 
T he i n vesti gat or s h o ul d be alerte d t o t he li keli h o o d of i m pr o per gl uc ose m eas ure me nt 
tec h ni q ue if a stu d y s u bject re p orts a n S M B G val u e < 5 5 m g/ d L t h at is n ot ass ociate d wit h a n y si g ns or s y m pt o ms of h y p o gl yce mia a n d is n ot treate d b y s o me f or m of gl uc ose a d mi nistrati o n.  
I n t he e ve nt of pr o ba ble s y m pt o matic h y p o gl yce mia, t he i n vesti gat or s h o ul d e nc o ura ge t he 
s u bject t o o btai n gl uc os e val ues, w he n p ossi ble, i n t he c o nte xt of si g ns a n d s y m pt o ms of 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665123] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 8  of 7 2  V 4 ( Gl o bal)  
 h y p o gl yce mia, e ve n if t h e gl u c ose val ue is meas ur e d after treat me nt f or t he s y m pt o ms is 
a d mi nistere d.  
If h y p o gl yce mia o cc urs i n a n y s u bj ect pres cri be d resc ue m e dicati o n f or h y per gl yce mia 
d uri n g t he st u d y, t he t otal dail y d ose of t h e res c ue me dicati o n s h o ul d be re d uce d 5 0 % or m ore at t he discr eti o n of t he i n vesti gat or . 
6. 1 6. 1 2  M aj or A d v er s e C ar di o v a s c ul ar E v e nt ( M A C E)  
E val uati o n of M A C E will be u n derta ke n acr oss t he de vel o p me nt pr o gra m f or be x a glifl ozi n. 
All M A C E re p orts s h o ul d als o be ca pt ur e d as S A Es a n d e ver y eff ort will be ma de t o e ns ur e t hat e ve nts rec or de d as M A C E are c o d e d i n a si milar ma n ner wit hi n t he safet y data b ase. T h e S A E listi n g will als o be re vie we d p eri o dicall y b y t he C E C me m bers t o i de ntif y p ote ntial M A C E t hat ma y n ot ha v e bee n r e p orte d b y t h e site i n vesti gat ors. I n vesti gat ors will f oll o w all s u bjects f or M A C E f or t h e d urati on of t he st u d y e v e n if st u d y me di cati o n has bee n per ma ne ntl y wit h dra w n. 
T he i n de pe n de nt C E C will recei ve a n d a dj u dicat e t he f oll o wi n g e v e nts.  • All deat hs  
• S us pecte d n o n- f atal m y o car dial i nf arcti o n ( MI) • S us pecte d h os pi[INVESTIGATOR_1314] o n f or u nsta ble a n gi na ( H U A) • S us pecte d tra nsie nt isc he mic attac k ( TI A) a n d str o ke  • S us pecte d h os pi[INVESTIGATOR_1314] o n f or heart fail ure ( H F) • Re p orte d c or o n ar y r e vas c ularizati o n pr oce d ur e  
6. 1 6. 1 3  Di a b eti c K et o a ci d o si s ( D K A)  
D K A is a seri o us, ac ute c o m plicati o n of dia betes a n d ca n be life-t hreate ni n g. S u b jects will be 
e d ucate d o n t h e si g ns a n d s y m pt o ms of D K A a n d are r e q uire d t o call t he st u d y cli nic a n d see k treat me nt s h o ul d s uc h si g ns a n d s y m pt o ms o cc ur.  
D uri n g t h e cli nical trial p eri o d, p ote ntial D K A will be m o nit ore d b y t he r o uti ne meas ure me nt 
of uri n ar y ket o n es a n d assess me nt f or si g ns or s y m pt o ms of aci d osis at e ver y cli nic visit. Cli nical prese ntati o ns, s uc h as diffic ult y br eat hi n g, a b d o mi nal pai n, na usea, v o miti n g, let har g y, or a fr uit y s mell i n t he breat h, or la b orat or y v al ues t hat s u g gest cli nicall y-si g nifica nt aci d osis s h o ul d be d oc u me nte d; treat me nt of D K A s h o ul d be pr o vi de d w h e n a p pr o pri ate.  
If o n g oi n g s y m pt o ms or si g ns s u g gest a p ossi ble D K A, t he i n vesti gat or s h o ul d perf or m 
rele va nt la b orat or y testi n g w hile dir ecti n g a p pr o priate me dical care f or t he s u bject. If D K A is s us pecte d, re gar dless of t he bl o o d gl uc os e le vel, t he f oll o wi n g assess me nts s h o ul d be d o ne i m me diatel y: p h ysical e x a m a n d ser u m gl uc ose, bi car b o nat e, electr ol yt es, a n d ser u m ket o nes meas ure d S T A T at a l ocal la b orat or y. If k et oaci d osis is li kel y, i n vesti gati o n al pr o d uct a d mi nistrati o n s h o ul d be disc o nti n ue d a n d i m me diate a p pr o priate me dical t hera p y, i ncl u di n g i ns uli n, s h o ul d be i nitiate d. A gl uc os e i nf usi o n ma y be pr o vi de d if necessar y t o a v oi d h y p o gl yce mia d uri n g i ns uli n t hera p y. I ns uli n treat me nt s h o ul d c o nti n ue u ntil res ol uti o n of t he ket oaci d osis a n d sta bilizati o n of t he s u bject’s cli nical c o n diti o n. I n v esti gati o nal pr o d u ct 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665124] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 4 9  of 7 2  V 4 ( Gl o bal)  
 a d mi nistrati o n ma y be res u me d f oll o wi n g sta bilizati o n of t he s u bject’s c o n diti o n. 
I n v esti gat or s h o ul d c ollect t he data necessar y f or t he c o m pleti o n of t he D K A C R F.  
If s y m pt o ms s u g gesti ve of D K A ma y h a ve occ urr e d b ut are n ot o n g oi n g, i n vesti gat or s h o ul d 
re vie w a v aila ble dat a i n or der t o c o m plete t h e D K A C R F. T he i n vesti gat or ma y als o perf or m la b orat or y ass ess me nt usi n g l ocal res o ur ces if necessar y f or cli nical care.  
6. [ADDRESS_665125] u g 
Dicti o nar y ( W H O - D D). A ta ble of c o n c o mita nt me dicati o ns base d o n t he A nat o mic 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665126] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 0  of 7 2  V 4 ( Gl o bal)  
 T hera p e utic C he mical ( A T C) classificati o n c o d e a n d preferre d n a me will b e pr o d uce d. A 
listi n g of c o nc o mita nt me dicati o ns will i ncl u de all me dicati o ns ta ke n b y a n y s u bjects d uri n g t he c o urse of t h e st u d y. 
6. [ADDRESS_665127] u d y e v al uati o ns a n d pr o ce d ures.  Reas o ns f or all wit h dra w als s h o ul d be rec or de d o n t he C R F. E x a m ples of reas o ns f or wit h dra wal i ncl u de:   
1.  A pr ot oc ol vi olati o n has occ urr e d , 
2.  A seri o us or i nt olera ble a d ve rse e v e nt has occ urr e d, 3.  A cli nicall y si g nifica nt c ha n ge i n a la b or at or y par a meter has o cc urre d ,  4.  T he s p o ns or or i n vesti gat or ter mi nates t he st u d y, or 5.  T he patie nt re q u ests t o be wit h dra w n  fr o m t he st u d y.  S u bjects w h o d o n ot c o m plete t he st u d y b ut w h o h a ve recei ve d i n v esti gati o nal pr o d uct s h o ul d ha ve a f oll o w- u p e x a mi nati o n, i ncl u di n g a p h ysical e x a mi nati o n, vital si g ns, E C G a n d cli nical la b orat or y tests acc or di n g t o  Secti o n [ADDRESS_665128] u d y pr oce d ures a n d meas ure me nts i n t his pr ot oc ol are wi del y use d a n d ge nerall y rec o g nize d as relia ble, acc ur ate, a n d rel e va nt f or s u bj ects wit h  T 2 D M.  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665129] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 1  of 7 2  V 4 ( Gl o bal)  
 [ADDRESS_665130] u d y 
pr oce d ur es ar e descri be d i n Secti o n 6 .  
A visit wi n d o w of ± 3 da ys is all o we d f or all visits e x ce pt visit V 3 . Visit 3 is t he da y of 
ra n d o mizati o n a n d t he basis f or t he visit wi n d o w.  
7. 1   S cr e e ni n g (3 d a y s t o 3 w e e k s b ef or e r u n -i n p eri o d, Vi sit V1)  
• E x plai n t he c o nte nt of t he i nf or me d c o ns e nt materials t o t he s u bject a n d c ollect si g ne d 
i nf or me d c o nse nt 
• C ollect nee de d i nf or m ati o n a n d e val uat e c o nf or ma nce t o  i ncl usi o n a n d e x cl usi o n criteria 
• O btai n me dical hist or y a n d de m o gra p hic i nf or m ati o n • Perf or m a n a b bre viat e d p h ysical e x a mi nati o n  • Meas ure b o d y wei g ht  • Meas ure vital si g ns, i ncl u di n g bl o o d press ur es a n d heart r ate • Perf or m a 1 2 -l ea d E C G meas ure me nt • Dra w bl o o d if a mi ni m u m 8- h fast has bee n c o m plete d b y t h e s u bject as d escri be d i n 
Secti o n 6. 1 1. 1 . T he s pecific la b orat or y t ests sc he d ule d f or t his visit are liste d i n A p pe n di x 2  
• C ollect a clea n -catc h, mi d-strea m uri ne s a m ple  
7. 2   Vi sit V 2 ( St art of R u n-i n) 
• C o u nsel s u bject o n a p pr o priate diet a n d e x ercis e • Dis pe nse r u n- i n kit f or r u n-i n peri o d • Assess a d vers e e ve nts a n d D K A assess me nt  • Rec or d me dicati o ns use d  
7. 3   Vi sit V 3 ( R a n d o mi z ati o n) 
• Perf or m a c o m plet e p h ysical e x a mi nati o n  • Meas ure b o d y wei g ht  • Meas ure vital si g ns, i ncl u di n g bl o o d press ur es a n d heart r ate • Dra w bl o o d if a mi ni m u m [ADDRESS_665131] as descri be d i n 
Secti o n 6. 1 1. 1 . T he s pecific la b orat or y t ests sc he d ule d f or t his visit are liste d i n A p pe n di x 2  
• C ollect a clea n -catc h, mi d -strea m uri ne s a m ple • Re vie w S M B G a n d gl yc e mic c o ntr ol rec or d  • C o nfir m t he eli gi bilit y a n d perf or m t he ra n d o mizati o n pr oce d ur es • Rec or d dr u g acc o u nta bilit y, c ollect r u n-i n b ottle a n d dis pe nse i n vesti gati o n al pr o d uct 
base d o n ra n d o mizati o n 
• A d verse e ve nts & D K A Assess me nts  • Rec or d me dicati o ns use d 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665132] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 2  of 7 2  V 4 ( Gl o bal)  
  
7. 4   Vi sit V 4 (w e e k 2 ) 
• Re vie w S M B G a n d gl yc e mic c o ntr ol rec or d  
• Rec or d dr u g acc o u nta bilit y • A d verse e ve nts & D K A Assess me nts  • Rec or d me dicati o ns use d • T his is a p h o ne visit. A site visit ma y be sc h e d ule d if cli nicall y n ee de d .  
7. 5   Vi sit V 5 ( w e e k 6) 
• Meas ure b o d y wei g ht  • Meas ure vital si g ns, i ncl u di n g bl o o d press ur es a n d heart r ate • Dra w bl o o d if a mi ni m u m [ADDRESS_665133] as d escri be d 
i n Secti o n 6. 1 1. 1 . T he s pecific la b orat or y tests sc h e d ule d f or t his visit are liste d i n A p pe n di x 2  
• C ollect a clea n -catc h, mi d-strea m uri ne s a m ple • C ollect bl o o d s peci me ns f or s pars e P K sa m pli n g fr o m selecte d s u bjects i n partici pati n g 
ce nters. Alter nati vel y, bl o o d sa m ples ca n be o n a n y of t he da ys d uri n g t he wee k of t he cli nical visit  
• Re vie w S M B G a n d gl yc e mic c o ntr ol rec or d  • Rec or d dr u g acc o u nta bilit y • A d verse e ve nts & D K A Assess me nts  • Rec or d me dicati o ns use d  
7. 6    Vi sit V 6 ( we e k 1 2 ) 
• Perf or m a n a b bre viat e d p h ysical e x a mi nati o n  • Meas ure b o d y wei g ht  • Meas ure vital si g ns, i ncl u di n g bl o o d press ur es a n d heart r ate •  Dra w bl o o d if a mi ni m u m 8- h fast has bee n c o m plete d b y t h e s u bject as d escri be d 
i n Secti o n 6. 1 1. 1 . T he s pecific la b orat or y tests sc h e d ule d f or t his visit are liste d i n A p pe n di x 2  
• C ollect a clea n -catc h, mi d-strea m uri ne s a m ple • C ollect bl o o d s peci me ns f or s pars e P K sa m pli n g fr o m selecte d s u bjects i n partici pati n g 
ce nters . Alter nati vel y, bl o o d sa m ples ca n be o n a n y of t he da ys d uri n g t he wee k of t he cli nical visit. 
• Re vie w S M B G a n d gl yc e mic c o ntr ol rec or d  • Rec or d dr u g acc o u nta bilit y, c ollect pre vi o us i n vesti gati o nal pr o d uct b ottle a n d d is pe nse 
ne w b ottle of i n vesti gati o nal pr o d uct base d o n ra n d o mizati o n 
• A d verse e ve nts & D K A Assess me nts  • Rec or d me dicati o ns use d  
7. 7   Vi sit V 7 ( w e e k 1 8) 
• Re vie w S M B G a n d gl yc e mic c o ntr ol rec or d  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665134] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 3  of 7 2  V 4 ( Gl o bal)  
 • Rec or d dr u g acc o u nta bilit y 
• A d verse e ve nts & D K A Assess me nts  • Rec or d me dicati o ns use d • T his is a p h o ne visit. A site visit ma y be sc h e d ule d if cli nicall y n ee de d.  
 
7. 8   Vi sit V 8 ( w e e k 2 4 ) 
• Perf or m a n a b bre viat e d p h ysical e x a mi nati o n  • Meas ure b o d y wei g ht  • Meas ure vital si g ns, i ncl u di n g bl o o d press ur es a n d heart r ate •  Dra w bl o o d if a mi ni m u m 8- h fast has bee n c o m plete d b y t h e s u bject as d escri be d 
i n Secti o n 6. 1 1. 1 . T he s pecific la b orat or y tests sc h e d ule d f or t his vi sit are liste d i n A p pe n di x 2  
• C ollect a clea n - catc h, mi d-strea m uri ne s a m ple • Perf or m a 1 2 -l ea d E C G meas ure me nt • Re vie w S M B G a n d gl yc e mic c o ntr ol rec or d  • Rec or d dr u g acc o u nta bilit y a n d c ollect pre vi o us i n vesti gati o nal pr o d u ct b ottle • A d verse e ve nts & D K A Assess me nts  • Rec or d me dicati o ns use d   
7. 9   Vi sit V 9 ( w e e k 2 6) 
• Perf or m a n a b bre viat e d p h ysical e x a mi nati o n  • Meas ure b o d y wei g ht  • Meas ure vital si g ns, i ncl u di n g bl o o d press ur es a n d heart r ate •  Dra w bl o o d if a mi ni m u m 8- h fast has bee n c o m plete d b y t h e s u bject as d escri be d 
i n Secti o n 6. 1 1. 1 . T he s pecific la b orat or y tests sc h e d ule d f or t his visit are liste d i n A p pe n di x 2  
• C ollect a clea n -catc h, mi d-strea m uri ne s a m ple • Re vie w S M B G a n d gl yc e mic c o ntr ol rec or d  • A d verse e ve nts & D K A assess me nts • Rec or d me dicati o ns use d  
7. [ADDRESS_665135] u g, f oll o wi n g t he s c h e d ule of e v e nts as o utli ne d i n vis it V 8. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665136] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 4  of 7 2  V 4 ( Gl o bal)  
 [ADDRESS_665137] u d y. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665138] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 5  of 7 2  V 4 ( Gl o bal)  
 9 P L A N N E D S T A TI S TI C A L M E T H O D S  
9. 1   G e n er al C o n si d er ati o n s 
T he f oll o wi n g s ecti o ns pr o vi de a s u m mar y of t h e pla n ne d a nal ysis of t he trial b ut a c o m plete 
statistical a nal ysis pla n will be de vel o pe d as a s e parate d oc u me nt a n d will be t he fi nal pla n. All statistical a nal yses will be perf or me d usi n g V ersi o n 9. 2 or later of Statistical A nal ysis S oft ware ( S A S
®). 
I n ge ner al, descri pti ve statistics ( n u m ber of s u bjects [ n], mea n, sta n dar d d e viati o n [ S D], Q 1, me dia n, Q 3, mi ni m u m, a n d ma xi m u m) will  be prese nte d f or c o nti n u o us varia bles, a n d fre q ue n c y a n d p erce nta ge f or cate g orical varia bl es.  
U nless ot her wise s pecifie d, all tests will be t w o -si de d usi n g a 0. 0 5 le vel of si g nifica n ce. All 
c o nfi de nce i nter vals ( CIs) will be t w o -si de d 9 5 % c o nfi de nce i nter vals.  
T he pri mar y s u peri orit y t est o n l o weri n g of H b A [ADDRESS_665139] b o will be c o n d ucte d at 0. 0 5 le vel of si g nifica n ce. If it is s uccessf ul, t he f oll o wi n g hier ar c hical testi n g str ate g y will be f oll o we d i n testi n g sec o n d ar y efficac y e n d p oi nts i n or d er t o preser ve e x peri me nt- wi de t y p e I err or at 0. 0 5:  
1.  S u peri orit y test of t he c h a n ge i n b o d y wei g ht i n s u bjects wit h baseli ne b o d y mass i n de x 
( B MI) ≥ 2 5 k g/ m
[ADDRESS_665140] olic bl o o d pr ess ure ( S B P) o ver ti me i n s u bjects wit h 
S B P ≥  [ADDRESS_665141] of t he c h a n ge i n H b A 1c o v er ti me i n s u bjects wit h e G F R 4 5 t o 
5 9 m L/ mi n/ 1. [ADDRESS_665142] of t he c h a n ge i n H b A 1c o v er ti me i n s u bjects wit h e G F R 3 0 t o 
4 4 m L/ mi n/ 1. [ADDRESS_665143] wit h a t w o-si de d 
si g nifica n ce at t he 5 % le vel a n d t he f oll o wi n g assu m pti o ns:  
1)  T he place b o -c orrecte d p o p ulati o n mea n c ha n ge fr o m baseli ne t o Wee k 2 4 i n H b A 1c 
i n t he d ose gr o u p of 2 0 m g wi ll be - 0. 4 %.  
2)  T he p o ole d sta n dar d d e vi ati o n f or t he c h a n ge fr o m baseli ne t o Wee k [ADDRESS_665144] b o gr o u ps will  be 1. 0%.  
 U n der t he a b o ve ass u m pti o ns, a n esti mate d sa m ple size of 1 3 3 e val ua ble s u bjects per treatme nt ar m yiel ds a p pr o xi matel y 9 0 % p o wer t o detect a tr eat me nt diff er e nce b et wee n be x a glifl ozi n a n d place b o. A sa m ple size of 1 5 0 per ar m h as bee n s electe d t o acc ou nt f or a 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665145] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 6  of 7 2  V 4 ( Gl o bal)  
 p ote ntial 1 2 % dr o p- o ut a n d t o all o w a de q uate s afet y e v al uati o n.  T he t otal sa m ple size f or 
t his st u d y will be [ADDRESS_665146] u d y will be c o n d u cte d at m ulti ple i n vesti gati ve sites a n d will li kel y i n v ol ve varia ble 
n u m bers of s u bjects at eac h site.  E nr oll me nt will be o n a c o m petiti ve basis b ut will be ca p pe d at 3 0 s u bjects fr o m eac h site.  
9. 3   A n al y si s P o p ul ati o n s  
9. 3. 1  I nt e nti o n-t o-tr e at A n al y si s S et 
All s u bjects w h o are ra n d o mize d will be i ncl u de d i n t he I nt e nti o n- t o-treat (I T T) A nal ysis Set.  
All a nal ys es of t he I T T a nal ysis set will be bas e d o n eac h s u bject’s ra n d o mize d assi g ne d treat me nt. T he I T T a nal ysis set will ser ve as t he pri mar y s et f or t he efficac y a nal ys es. 
9. 3. [ADDRESS_665147] uall y ta k e n. T he Saf et y A nal ysis Set  is t he pri mar y a n al ysis set f or safet y e v al uati o n . 
9. 3. 3  P er Pr ot o c ol A n al y si s S et  
T he Per Pr ot oc ol ( P P) A nal ysis Set will i ncl u de all s u bjects i n t he I T T a nal ysis set w h o meet 
t he st u d y eli gi bilit y re q uire me nts a n d ha v e n o maj or pr ot oc ol de viati o ns t hat aff ect t he vali dit y of t he efficac y m eas ure m e nts.  Pr ot oc ol de viati o ns t hat ma y res ult i n s u bject e x cl usi o n fr o m t he P P A nal ysis Set will be detaile d i n t he Statistical A nal ysis Pla n.  
9. [ADDRESS_665148] eri sti c s 
De m o gra p hic a n d  baseli n e c har acteristics will be s u m marize d descri pti vel y base d o n t he I T T a n d P P (if a p plica ble) a n al ysis sets f or eac h treat me nt gr o u p as well as f or all s u bjects c o m bi ne d. Ke y varia bles i ncl u de a ge, ge n der, race, et h nicit y, bas eli ne H b A 1 c val ues, bl o o d press ure, b o d y w ei g ht, b o d y mass i n de x ( B MI i n k g/ m
2), fasti n g pl as ma gl uc ose le vel, e G F R, 
a n d a nti-dia betic tr eat me nt stat us at scree ni n g (i ncl u di n g t y p e of t hera p y us e d [treat me nt naï ve, metf or mi n, s ulf o n yl urea, D P P- [ADDRESS_665149], i ns uli n). I n ge n eral, b aseli ne meas ure m e nt is defi n e d as t he last meas ure me nt pri or t o t he first d ose of d o u ble- bli n d me dicati o n. 
9. 5   A n al y si s of Effi c a c y 
All efficac y a n al ys es will be perf or me d bas e d o n t he I T T a n al ysis set. T h e pri mar y e n d p oi nt a nal ysis will als o be c o n d ucte d usi n g t he P P A nal ysis Set (if dee me d diff er e nt fr o m I T T a nal ysis s et).  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665150] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 7  of 7 2  V 4 ( Gl o bal)  
 F or t he pri mar y e n d p oi nt of H b A 1c c ha n ge fr o m baseli ne o ver 2 4 wee ks of treat me nt , t he 
M M R M a nal ysis of c o v aria nce m o del ( A N C O V A) wit h baseli ne H b A [ADDRESS_665151] i ncl u di n g t he s c h e d ule d a n d t he u nsc h e d ul e d visits f or meas ure m e nt of H b A 1c (Nati o nal Researc h C o u ncil, 2 0 1 0 ). Treat me nt, visit , treat me nt-b y -visit,  a n d stratificati o n fact ors f or ra n d o mizati o n ( H b A 1c le v el [ 7. 0 t o 8. 5 % or 8. 6 t o 1 0. 5 %), scree ni n g a nti-dia b etic treat me nt re gi me n [i ns uli n treate d, ot her], e G F R [ 3 0- 4 4 or 4 5- 5 9 m L/ mi n/ 1. 7 3 m
2] will be 
a p plie d as fi x e d eff ects. Fr o m t h is m o del, a n esti mate of t he treat me nt diff ere nce at w ee k [ADDRESS_665152] ur e d oes n ot c o n ver ge, a n a ut ore gressi ve( 1) c o v aria n ce str uct ure will be us e d. H b A 1c val ues o btai ne d after t he start of resc ue m e dicati o n will n ot be e x cl u de d fr o m t his pri mar y a n al ysis.  
T he M M R M m o del is o ne a p pr oac h t o o btai n treat me nt effect esti mates i n t he prese n ce of 
missi n g data. As se nsiti vit y a n al ys es f or missi n g d ata, t he f oll o wi n g will be perf or me d:  
1)  Missi n g H b A 1c d ata will be i m p ute d via m ulti ple i m p utati o n ( MI), f oll o w i n g w hic h 
t he M M R M will be re peate d o n t he c o m plete datas ets wit h res ults c o m bi ne d acr oss c o m plete datasets usi n g sta n dar d MI tec h ni q ues; H b A 1c val ues c ollecte d after t he start of resc u e me dicati o n will n ot be c o nsi dere d missi n g. 
2)  Missi n g H b A 1c d ata will be  i m p ute d via L O C F, f oll o wi n g w hic h t he M M R M will be 
re peat e d; H b A 1c v al ues c ollecte d after t he start of resc ue m e dicati o n will be c o nsi dere d missi n g. 
3)  H b A 1c val ues c ollecte d after t he start of r esc ue m e dicati o n will be c o nsi dere d 
missi n g , a n d t he M M R M a nal ys es will be re -perf or me d.  
 If it is dee me d t hat t he P P a nal ysis set is differe nt fr o m t he I T T a n al ysis set, sa me a nal yses as descri be d a b o ve will be c o n d ucte d i n P P a nal ysis s et as well. 
9. 5. [ADDRESS_665153] o p o ut s P att er n  
T he earl y t er mi nati o n rat e is esti mate d t o be 1 2 %. T o t he e xte nt p ossi ble, atte m pts will be 
ma de t o mi ni mize t he a m o u nt of missi n g data t hr o u g h meas ures pla n n e d i n t he st u d y c o n d uct. 
T he n u m ber, ti mi n g, p atter n, reas o n f or a n d p ossi ble i m plicati o ns of missi n g val u es i n 
efficac y ass ess me nts will be i n vesti gat e d. T he dr o p o ut patter ns will be assesse d b y K a pla n-Meier pl ots if a p plica ble t o assess w het her t h e y differ b et wee n treat me nt gr o u ps.  
9. [ADDRESS_665154] o n t he c ha n ge of b o d y w ei g ht i n s u bjects wit h  baseli ne B MI ≥ 2 5 k g/ m
2 at wee k 2 4, a n a nal ysis of c o varia nce m o del ( A N C O V A) will be i m ple me nte d 
usi n g all a vaila bl e data at wee k 2 4 ( v al ues o btai ne d after t he start of r esc ue me dicati o n will n ot be e x cl u de d i n t he a n al ysis). M M R M m o deli n g a p pr oac h will b e utilize d. T
he m o del will 
i ncl u de  treat me nt, visit, treat me nt-b y -visit, r a n d o mizati o n stratificati o n fact ors, a n d t he 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665155] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 8  of 7 2  V 4 ( Gl o bal)  
 baseli ne wei g ht val ue as fi x e d effects/c o v ariates. Least s q uar es mea n tr eat me nt differe n ces 
bet wee n t he b e x a glifl ozi n a n d place b o will be esti mate d fr o m t he m o del. T he c orr es p o n di n g 9 5 % CI a n d p- val u e will be pr o vi de d. 
T he c ha n ge i n s yst olic bl o o d press ure ( S B P) i n s u bjects wit h baseli ne S B P ≥ [ADDRESS_665156] b o at wee k 2 4 will be a n al yze d usi n g t he similar met h o d wit h baseli ne S B P meas ure as a c o variate. T he sa me a n al ysis met h o d a p plies f or t he testi n g of c h a n ges i n H b A 1c at wee k 2 4 f or s u bj ects wit h baseli ne e G F R 4 5-5 9 m L/ mi n/ 1. 7 3 m
2, a n d f or s u bjects wit h baseli ne e G F R 3 0- 4 4 m L/ mi n/ 1. 7 3 m2. 
All a nal ys es will be c o n d ucte d i n I T T a n al ysis set. A hierar c hical testi n g pr oce d ure will be a p plie d t o a b o ve f o ur e n d p oi nts i n t he se q ue nce pr o vi de d i n Secti o n 9. 1 . 
9. 7   Ot h er Effi c a c y A n al y s e s  
C ha n ges i n H b A 1c, F P G, S B P/ D B P, b o d y wei g ht, a n d al b u mi n le vel i n uri ne f or all s u bjects d uri n g t he tr eat me nt peri o d will be s u m marize d descri pti vel y b y eac h ti me p oi nt (i.e., Wee ks 6, 1 2, 2 4). I n a d diti o n, t hese e n d p oi nts ma y be a nal yz e d usi n g a si milar M M R M  m o del as use d f or t he pri mar y a nal ysis of H b A [ADDRESS_665157] b o.  
C u m ulati ve s u m mar y o n t he pr o p orti o n of s u bjects ac hie vi n g H b A 1 c  < 7 %, a n d t he 
pr o p orti o n of s u bjects ac hie vi n g b o d y w ei g ht r e d ucti o n of at least 5 % will als o be prese nte d.  
A nal ys es will be c o n d uct e d usi n g I T T a nal ysis set. 
9. 8  A n al y si s of S af et y  
All safet y a nal yses will be c o n d ucte d b ase d o n t he Safet y A nal ysis Set.  Safet y d ata will i ncl u de A Es, p h ysical e x a m res ults, vital si g ns, E C G res ults, a n d cli nical la b 
meas ure me nts of  s er u m c he mistr y, he m at ol o g y, ser u m li pi [INVESTIGATOR_805], gl yce mic c o ntr ol para met ers a n d uri ne s peci me ns.  O bser ve d dat a will be s u m marize d usi n g des cri pti ve statistics b y treat me nt gr o u p bas e d o n t he Safet y A nal ysis Set . 
9. 8. 1  A d v er s e E v e nt s  
A d verse e ve nts wi ll be ma p pe d t o preferre d ter m a n d b o d y s yste m usi n g t he Me dical 
Dicti o nar y f or Re g ul at or y A cti vities ( Me d D R A). A E rec or ds t hat be gi n at or after t h e first a d mi nistrati o n of i n vesti gati o nal pr o d u cts ar e c o nsi dere d treat me nt e mer ge nt A Es ( T E A Es). T he n u m ber a n d p erce nta ge of s u bjects r e p orti n g T E A Es will be s u m marize d f or eac h treat me nt gr o u p b y Me d D R A s yste m or ga n class a n d pref err e d ter m. F urt h er s u m maries b y se verit y, a n d b y r elati o ns hi p t o st u d y tr eat me nt will als o be pr o vi de d. Dr u g-relate d A Es will be c o nsi der e d t h ose t o be at least p ossi bl y r elate d t o i n vesti gati o nal pr o d u ct base d o n t he i n vesti gat or’s assess me nt. T he n u m ber a n d p erce nta ge of s u bjects r e p orti n g seri o us A Es, a n d t he n u m ber a n d perce nta ge of s u bjects r e p orti n g A Es lea di n g t o treat me nt disc o nti n uati o n will als o be s u m marize d f or eac h treat me nt gr o u p b y Me d D R A s yste m or ga n class a n d preferre d t er m.  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665158] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 5 9  of 7 2  V 4 ( Gl o bal)  
 9. 8. [ADDRESS_665159] atistical a nal ysis pla n t o e val uate ot her e ve nt a ss ociate d saf et y para meters a n d p ote ntial ris ks i n s u b p o p ulati o ns base d o n a ge, ge n der, or ot her baseli ne c haracteristics (if s a m ple size all o ws) . 
9. 8. 3  Cli ni c al a n d L a b or at or y E v e nt s a n d A n al y s e s  
Cli nical a n d la b orat or y p ara meters  will be  meas ur e d at baseli ne , d uri n g t h e treat me nt peri o d  
a n d at f oll o w- u p.  T hes e varia bles i ncl u de vital si g ns ( bl o o d pr ess ure, p uls e, res pi[INVESTIGATOR_1313] o n r ate, a n d te m perat ure), cli nical la b orat or y o utc o mes a n d E C G data . T he y will be s u m marize d as act ual val ues a n d c ha n ges fr o m baseli ne b y treat me nt f or eac h visit f or selecte d par a meters. 
La b orat or y d ata will be classifie d as l o w, n or mal or hi g h r elati ve t o t h e par a meter’s ref ere n ce 
ra n ge. La b orat or y a b n or malities f or eac h treat me nt will als o be s u m marize d wit h s hift ta bles  f or select e d par a meters. 
9. 8. [ADDRESS_665160] u d y data b ase. 
A n i n de pe n de nt D ata a n d Safet y M o nit ori n g B oar d ( D S M B) will m o nit or t he safet y of t h e 
s u bjects i n t his st u d y.  T h e o bjecti ves of t he D S M B ar e t o assess dr u g s afet y a n d t o all o w f or pr ot oc ol m o dificati o n or earl y st o p pi n g d u e t o saf et y c o ncer ns. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665161] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 0  of 7 2  V 4 ( Gl o bal)  
 [ADDRESS_665162] d etails of partici pati n g i n ve sti gat ors, m o nit ors, cli nical la b orat ories, a n d tec h ni cal de part me nts a n d/ or i nstit uti o ns, as well as i nf or mati o n o n me m bers of a d diti o nal st u d y c o m mittees, will be f o u n d i n t he st u d y files of t he i n vesti gati o nal site . 
[ADDRESS_665163] be s u b mitte d t o t he I nstit uti o nal Re vie w B oar d (I R B) or I n d e pe n de nt Et hics C o m mittee (I E C) f or re vie w a n d m ust be a p pr o ve d b y t he s p o ns or a n d t he I R B /I E C bef ore t h e st u d y is i nitiate d. A n y a me n d me nts or a d d e n da t o t he pr ot oc ol m ust als o be a p pr o ve d b y t h e I R B /I E C pri or t o i m ple me nti n g c ha n ges i n t he st u d y. T he i n v esti gat or is re s p o nsi ble f or k ee pi n g t he I R B/I E C i nf or me d of t he pr o gress of t he st u d y a n d of a n y c ha n ges ma de t o t he pr ot oc ol as dee me d a p pr o priate, b ut i n a n y case at least o nce a year. T he i n vesti gat or m ust als o kee p t he I R B /I E C i nf or me d of a n y S A Es o cc urri n g t o s u bjects u n der t heir s u per visi o n. 
[ADDRESS_665164] u d y are desi g n e d t o e ns ure t hat t he s p o ns or a n d i n vesti gat or f oll o w I nter nati o nal C o nfere nce of Har m o nisati o n G C P G ui deli nes ( E 6) a n d t he g ui di n g pri nci ples detaile d i n t he Declarati o n of Helsi n ki.  T he st u d y will als o be carri e d o ut i n kee pi n g wit h a p plica ble l ocal la ws a n d re g ulati o ns.  A n i ns pecti o n b y t he s p o ns or re pr ese ntati ves a n d/ or t heir desi g n ee a n d/ or  ot her a ut h orize d re g ul at or y a ut h orities re pr ese ntati ves ma y occ ur at a n y ti me. T he i n vesti gat or m ust a gr ee t o t he i ns pecti o n of st u d y-relate d rec or ds b y t he r e g ulat or y a ut h orit y/s p o ns or r e pres e ntati ves, a n d m ust all o w direct access t o s o urce d o c u me nts t o t he re g ulat or y a ut h orit y/s p o ns or re pr ese ntati ves. 
T he i n vesti gat or is res p o nsi ble f or c o m pl yi n g wit h t he pr ot oc ol a n d all a p pr o priate 
re g ulati o ns a n d g ui deli nes g o ver ni n g gl o b al cli nical researc h. A d diti o nall y, he/s he is res p o nsi ble f or e ns uri n g t hat all partici pati n g staff me m bers ar e a de q u atel y trai ne d a n d c o m pete nt t o perf or m his/ her assi g ne d tas ks. 
M o dificati o ns t o t he st u d y pr ot oc ol will n ot be i m ple me nte d b y eit her t he s p o ns or or t he 
i n vesti gat or wit h o ut a gr ee me nt b y b ot h p arties. H o we ver, t he i n v esti gat or ma y i m ple me nt a de viati o n fr o m or a c ha n ge of t he pr ot oc ol t o eli mi nate a n y i m me diate hazar ds t o t he trial s u bjects wit h o ut pri or I R B/I E C or s p o ns or a p pr o v al/fa v ora bl e o pi [INVESTIGATOR_9384] o n. As s o o n as p ossi ble, t he i m ple me nte d de viati o n or c ha n ge, t h e reas o ns f or it, a n d if a p pr o pri ate, t he pr o p ose d pr ot oc ol a me n d me nt s h o ul d be s u b mitte d t o t he I R B/I E C a n d s p o ns or. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665165] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 1  of 7 2  V 4 ( Gl o bal)  
 A n y d e viati o ns fr o m t he pr ot oc ol m ust be f ull y e x plai ne d a n d d oc u me nt e d b y t he 
i n vesti gat or. T h e cir c u msta nces, acti o n ta ke n, a n d i m pact of t he de viati o n o n t he trial m ust be c o m m u nicate d b y t he pri nci pal i n vesti gat or t o t he desi g nat e d me dical m o nit or. A n y s u bse q ue nt acti o ns will be assesse d b y t he d esi g nate d me dical m o nit or a n d d oc u me nte d. 
[ADDRESS_665166] ha ve recei ve d fr o m t he I E C or I R B t he writte n a p pr o v al or fa v ora ble o pi [INVESTIGATOR_9384] o n of t he i nf or me d-c o nse nt f or m a n d a n y ot h er writte n i nf or matio n t o be pr o vi de d t o s u bjects. T he writte n a p pr o val of t he I R B /I E C t o get her with t he a p pr o ve d s u bject i nf or mati o n/ i nf or me d c o nse nt f or ms m ust be file d.  T he i nf or me d c o nse nt f or m m ust c o ntai n all ele me nts re q uir e d b y a ut h orize d r e g ulat or y a ut h orities a n d I C H G C P g ui deli nes. 
Writte n i nf or me d c o nse nt m ust be o btai ne d bef ore a n y st u d y- s p ecific pr oce d ure ta kes place.  
Partici pati o n i n t he st u d y a n d date of i nf or me d c o nse nt gi ve n b y t he s u bj ect s h o ul d be d oc u me nte d a p pr o p riatel y i n t he s u bject’s files. A c o p y of t he si g ne d i nf or me d c o nse nt f or m m ust be pr o vi de d t o t he s u bject. If a p plica ble, it will be pr o vi de d i n a certifie d tra nslati o n i n t he la n g u a ge u n d erst o o d b y t he s u bject, if n ot E n glis h.  Si g ne d c o nse nt f or ms m ust re mai n i n eac h s u bject’s st u d y file a n d m ust be a vaila ble f or verificati o n b y st u d y m o nit ors at a n y ti me.  
[ADDRESS_665167]’s per missi o n. T o e ns ure c o m plia nce wit h c urr e nt I C H g ui deli nes, d ata ge n erate d b y t his st u d y m ust be a vaila ble f or i ns pecti o n u p o n re q uest b y r e prese nt ati ves of nati o nal a n d l ocal healt h a ut h orities, t he s p o ns or, a n d t he I R B/I E C f or eac h st u d y site. St u d y i nf or m ati o n fr o m t his pr ot oc ol will be p oste d o n cli nicaltrials. g o v a n d a n y l ocal re g ulat or y re gistr y we bsites, as re q uire d b y r e g ulati o n. 
S u bject na mes a n d ot her i de ntifiers, s uc h as p h ot o gr a p hs, a u di o, or vi de ota pes, ma y n ot be 
discl ose d i n a n y p u blicati o n wit h o ut pri or writte n a ut h orizati o n fr o m t he s u bject. 
[ADDRESS_665168] u d y dat a, s u bjects’ me dical rec or ds, a n d C R Fs i n acc or da n ce wit h I C H g u i deli nes, G C Ps, a n d t he res pecti ve nati o nal a n d l ocal g o ver n me nt re g ulati o ns a n d g ui deli nes. 
T he i n vesti gat or will per mit a ut h orize d re prese ntati ves of t he s p o ns or a n d t he res pecti ve 
nati o nal or l ocal healt h a ut h orities , ot her a ut h orize d re g ulat or y a ut h orities, a n d I R B/I E C t o i ns pect facilities a n d r ec or ds rele va nt t o t his st u d y. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665169] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 2  of 7 2  V 4 ( Gl o bal)  
 [ADDRESS_665170] c o nse nt e d, a case r e p ort f or m ( C R F), i n electr o ni c f or mat, will be s u p plie d 
a n d mai ntai ne d b y t he C R O staff a n d si g ne d b y t he i n vesti gat or or a ut h ori ze d desi g nee t o i n dicate t hat he/s he has r e vie we d a n d a gr ees wit h t he e ntere d d ata. T his als o a p plies t o t h ose s u bjects w h o fail t o c o m plete t he trial. T he r eas o n f or s u bject wit h dra wal m ust be rec or d e d i n t he case re p ort f or m. 
E ntrie s ma de i n t he C R F m ust be verifia ble a gai nst s o urce d oc u me nts. S o ur ce d oc u me nts are 
defi ne d as all me dical rec or ds, me dical n otes, la b orat or y res ults, E C G traces a n d a n y a d diti o nal d oc u me nt ot her t ha n t he C R F t hat has ori gi nal s u bject i nf or mati o n c o ntai ne d wit hi n it.  
All C R Fs a n d s o urce d o c u me nts s h o ul d be c o m plete d f oll o wi n g G C P a n d t he C R O’s 
sta n dar d o per ati n g pr oce d ures. 
1 0. 8   D at a a n d S af et y M o nit ori n g B o ar d 
A n i n de pe n de nt D ata a n d Safet y M o nit ori n g B oar d ( D S M B) will m o nit or o verall saf et y i nf or mati o n d uri n g t he b e x a glifl ozi n de vel o p me nt pr o gra m. T he s afet y r e vi e w acti vit y a n d p ote ntial ris k be nefit assess me nts utilize d b y t he D S M B will be defi ne d i n its c harter.  
1 0. 9   Pr ot o c ol Vi ol ati o n s/ D e vi ati o n s 
It is i m p orta nt t o c o n d uct t he st u d y acc or di n g t o t h e pr ot oc ol.  Pr ot oc ol de vi ati o n wai vers  will n ot be pr os pecti vel y gr a nte d b y t he s p o ns or. If mi n or pr ot oc ol de viati o ns occ ur, t he i n vesti gat or m ust deci d e t he m ost a p pr o priate w a y t o pr ocee d wit h st u d y acti vities a n d s h o ul d c o ns ult t he st u d y re pres e ntati ve f or assista nce. If m aj or pr ot oc ol de viati o ns occ ur, t he s p o ns or’s me dical m o nit or m ust be n otifie d i m me diatel y s o t hat a d ecisi o n a b o ut w het her t o kee p t he s u bject i n t he st u d y ca n be ma d e.  
O nl y if a n e mer ge nc y o cc urs t hat re q uir es a de p art ure fr o m t he pr ot o c ol f or a n i n di vi d ual 
s u bject ca n t here be a de part ure wit h o ut t he s p o ns or’s pre-a p pr o v al. T he nat ure a n d r eas o ns f or t he pr ot oc ol de vi ati o n will be rec or d e d i n t he s u bject’s C R F, a n d t he pri nci pal i n vesti gat or m ust n otif y t he S p o ns or. 
Pr ot oc ol vi olati o ns/ de viati o ns m ust be re p orte d i n t he fi nal st u d y r e p ort. 
[ADDRESS_665171] u d y data, s u bjects’ 
me dical rec or ds, a n d C R Fs i n acc or da n ce wit h I C H g ui deli nes, G C Ps, a n d t he res pecti ve l ocal a n d nati o nal g o ver n me nt re g ulati o ns a n d g ui deli nes. 
T he i n vesti gat or will per mit a ut h orize d re prese ntati ves of t he s p o ns or a n d t he res pecti ve 
nati o nal or l ocal healt h a ut h orities, ot her a ut h orize d re g ulat or y a ut h orities, a n d I R B/I E C t o i ns pect facilities a n d r ec or ds rele va nt t o t his st u d y. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665172] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 3  of 7 2  V 4 ( Gl o bal)  
 Eac h ce nter will be visite d at re g ular i nter vals b y a m o nit or t o e ns ure c o m plia nce wit h t he 
st u d y pr ot oc ol, G C P, a n d le gal as pects. T his will i ncl u de o n-site c h ec ki n g of t he C R Fs f or c o m plete ness a n d clarit y, cr oss -c h ec ki n g wit h s o urce d oc u m e nts, a n d clarificati o n of a d mi nistrati ve matters.  
All C R F data will be e nt ere d i nt o a cli nical data b ase. F oll o wi n g t he c orrecti o n of a n y err ors, 
t he cli nical data bas e will be l oc ke d. 
[ADDRESS_665173] a ws fr o m t he trial a n d reli n q uis hes his/ her res p o nsi bilit y f or t he 
mai nte na nce a n d ret e nti o n of rec or ds, he/s he m ust n otif y t he s p o ns or i n writi n g s o t hat arra n ge me nts ca n b e ma d e t o pr o perl y st ore t h e trial materials.  
[ADDRESS_665174] u d y are re p orte d i n me dical j o ur nals or at meeti n gs, all s u bjects’ i d e ntities will re mai n c o nfi de ntial. 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665175] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 4  of 7 2  V 4 ( Gl o bal)  
 1 1  R E F E R E N C E LI S T  
( 1 9 9 8a). I nte nsi v e bl o o d- gl uc ose c o ntr ol wit h s ul p h o n yl ureas or i ns uli n c o m pare d wit h 
c o n ve nti o nal treat me nt a n d ris k of c o m plicati o ns i n patie nts wit h t y pe 2 dia betes ( U K P D S 3 3). T he La n cet  3 5 2, 8 3 7- 8 5 3. 
( 1 9 9 8 b). Ti g ht bl o o d press ure c o ntr ol a n d ris k of macr o vas c ular a n d micr o vasc ular 
c o m plicati o ns i n t y pe 2 dia betes: U K P D S [ADDRESS_665176] u d y Gr o u p. B mj  3 1 7 , 7 0 3- 7 1 3. 
A merica n Di a betes, A. ( 2 0 1 4). Sta n dar ds of me di cal care i n dia bet es --[ADDRESS_665177] 1 , S 1 4- 8 0. 
Ca va na u g h, K. ( 2 0 0 7). Dia betes ma na ge me nt iss ues f or patie nts wit h c hr o nic ki d ne y disease. 
Cli n Dia betes, 9 0- 9 7. 
C oll- de- T uer o, G., M ata- Cases, M., R o dri g uez- P o ncelas, A., Pe pi o, J. M., R o ura, P., Be nit o, 
B., Fra nc h- Na d al, J., a n d Saez, M. ( 2 0 1 2). C hr o nic ki d ne y disease i n t he t y pe 2 dia betic patie nts: pre vale n ce a n d a ss ociate d varia bles i n a ra n d o m sa m ple of 2 6 4 2 p atie nts of a Me diterra n ea n area. B M C ne p hr ol o g y  1 3, 8 7. 
Gil bert, R. E. ( 2 0 1 4). S o di u m- gl uc ose li n ke d tr a ns p orter- 2 i n hi bit ors: p ote ntial f or 
re n o pr otecti o n be y o n d bl o o d gl uc os e l o weri n g? Ki d ne y i nter n ati o nal 8 6, 6 9 3- 7 0 0. 
I nz ucc hi, S. E., Ber ge nstal, R. M., B use, J. B., Dia ma nt, M., Ferra n ni ni, E., N a uc k, M., Peters, 
A. L., Ts a pas, A., We n der, R., Matt he ws, D. R. , et al. ( 2 0 1 2). Ma na ge me nt of h y p er gl yce mia i n t y pe 2 dia b etes: a patie nt-ce nter e d a p pr o ac h: p ositi o n state me nt of t he A merica n Dia b etes Ass ociati o n ( A D A) a n d t he E ur o pea n Ass ociati o n f or t he St u d y of Dia betes ( E A S D). Dia betes care  [ADDRESS_665178], J. F. ( 2 0 1 4). L o n g- ter m st u d y of patie nts wit h 
t y pe 2 dia b etes a n d mo derate r e nal i m pair me nt s h o ws t hat da pa glifl ozi n re d uces wei g ht a n d bl o o d press ure b ut d oes n ot i m pr o ve gl yce mic c o ntr ol. Ki d ne y i nter nati o nal  8 5, 9 6 2- 9 7 1. 
Nati o nal Resear c h C o u ncil ( 2 0 1 0). T he Pre v e nti o n a n d Treat me nt of Missi n g D ata i n Cli nical 
Trials. I n  9 7 8- 0- 3 0 9- 1 5 8 1 4- 5, N. R. C o u ncil, e d., p p. 1 6 2. 
Sa nter, R., Ki n ner, M., Lasse n, C. L., Sc h n e p pe n h ei m, R., E g gert, P., Bal d, M., Br o de hl, J., 
Dasc h ner, M., E hric h, J. H., Ke m per, M. , et al. ( 2 0 0 3). M olec ular a nal ysis of t he S G L T 2 ge ne i n patie nts wit h re nal gl uc os uria. J A m S oc Ne p hr ol 1 4, 2 8 7 3- 2 8 8 2. 
Sc hee n, A.J. ( 2 0 1 5). P har mac o ki netics, P har mac o d y na mics a n d Cli nical Use of S G L T 2 
I n hi bit ors i n Patie nts wit h T y pe 2 Dia betes M ellit us a n d C hr o nic Ki d ne y Disease. Cli nical p har mac o ki netics  5 4, 6 9 1- 7 0 8. 
T ur ner, R. C., C ull, C. A., Fri g hi, V., a n d H ol ma n, R. R. ( 1 9 9 9). Gl yce mic c o ntr ol wit h diet, 
s ulf o n yl ur ea, metf or mi n, or i ns uli n i n patie nts wit h t y pe 2 dia b etes mellit us: pr o gressi ve 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665179] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 5  of 7 2 V 4 ( Gl o bal)  
 re q uire me nt f or m ulti ple t hera pi[INVESTIGATOR_014] ( U K P D S 4 9). U K Pr os pecti ve Dia b etes St u d y ( U K P D S) 
Gr o u p. J A M A  2 8 1, 2 0 0 5- 2 0 1 2. 
va n de n He u v el, L. P., Assi n k, K., Wille mse n, M., a n d M o n ne ns, L. ( 2 0 0 2). A ut os o mal 
recessi ve re n al gl u c os uri a attri b uta ble t o a m utati o n i n t he s o di u m gl uc ose c otra ns p orter ( S G L T 2). H u ma n ge n etics 1 1 1, 5 4 4- 5 4 7. 
Vi via n, E. ( 2 0 1 5). S o di u m- Gl uc ose C otra ns p orter 2 I n hi bit ors i n t he Tr eat me nt of T y p e 2 
Dia betes Mellit us. T he Dia betes e d ucat or.  
W hale n, K., Miller, S., a n d O n ge, E. S. ( 2 0 1 5). T h e R ole of S o di u m- Gl uc ose C o -Tra ns p ort er 
2 I n hi bit ors i n t he Tr eat me nt of T y p e 2 Dia b etes. Cli nical t hera pe utics  3 7, 1 1 5 0- 1 1 6 6. 
Yale, J. F., Ba kris, G., Cari o u, B., Y ue, D., Da vi d- Net o, E., Xi, L., Fi g uer oa, K., Wajs, E., 
Usis ki n, K., a n d Mei ni n ger, G. ( 2 0 1 3). Efficac y a n d safet y o f ca na glifl ozi n i n s u bjects wit h t y pe 2 dia b etes a n d c hr o nic ki d ne y disease. Di a bet es, o besit y & meta b olis m 1 5, 4 6 3- 4 7 3. 
Zi n ma n, B., Wa n ner, C., Lac hi n, J. M., Fitc hett, D., Bl u h m ki, E., Ha ntel, S., Matt he us, M., 
De vi ns, T., J o ha nse n, O. E., W oerle, H.J. , et al. ( 2 0 1 5). E m pa glifl ozi n, Car di o vasc ular O utc o mes, a n d M ortalit y i n T y pe 2 Dia betes. T h e Ne w E n gla n d j o ur n al of me dici ne  3 7 3, 2 1 1 7- 2 1 2 8. 
    
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665180] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 6  of 7 2  V 4 ( Gl o bal)  
 A p p e n di x 1   S c h e d ul e of E v e nt s 
Pr oce d ure  Scree ni n g  R u n -i n Tre at me nt  F oll o w -u p  
Visit N u m b er  V 1  V 2  V 3  V 4  V 5  V 6  V 7  V 8  V 9  
Ti me t o R a n d o miz ati o n  3 d a ys - 3 
w ee ks  t o V 2 - 1 0 2 6 1 2  1 8  2 4  2 6  
I nf or me d C o nse nt X          
Scree ni n g f or I/ E Criteria  X   X        
Me dical Hist or y  X          
Diet a n d E xercise C o u nseli n g   X         
P h ysical E xa mi nati o n    X        
A b bre viate d P h ysical E xa mi nati o n  X      X   X  X  
W ei g ht  X   X   X  X   X  X  
Vital Si g ns  X   X   X  X   X  X  
Electr ocar di o gra p h y  X        X   
Cli nical La b orat or y T ests  X   X   X  X   X  X  
Uri nal ysis  X   X   X  X   X  X  
P o p ulati o n P K Sa m pli n g      X  X     
Diar y a n d Gl uc o meter Rec or d Re vie w    X  X  X  X  X  X  X  
Dis pe nsi n g R u n -i n Dr u g  X         
Ra n d o mizati o n    X        
Dis pe nsi n g I n vesti gati o nal Pr o d uct    X    X     
A d verse E ve nts & D K A Assess me nts   X  X  X  X  X  X  X  X  C o nc o mita nt Me dicati o n Assess me nts   X  X  X  X  X  X  X  X  
 
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665181] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 7  of 7 2  V 4 ( Gl o bal)  
 A p p e n di x [ADDRESS_665182] s 
Pr oce d ure  Scree ni n g  R u n -i n Tre at me nt  F oll o w -
u p  
Visit n u m ber  V 1  V 2  V 3  V 4  V 5  V 6  V 7  V 8  V 9  
Ti me t o Ra n d o mizati o n Visit ( wee ks)  [ADDRESS_665183] ( W O C B P)  X   X   X  X   X  X  
P o p ulati o n P K sa m pli n g      X  X     
 
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665184] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 8  of 7 2  V 4 ( Gl o bal)  
 A p p e n di x [ADDRESS_665185] a g e D efi niti o n 
C hr o nic ki d ne y disease ( C K D) is defi ne d as eit her ki d ne y d a ma ge or G F R < 6 0 
m L/ mi n/ 1. 7 3 m3 f or ≥ [ADDRESS_665186] u dies ( N F K K D O Q g ui deli nes ). 
Sta ges of C K D ar e  o utli ne d i n Ta ble 2.  
T a bl e  [ADDRESS_665187] a ge  Descri pti o n  G F R ( m L/ mi n/ 1. 7 3 m2) 
1  Ki d ne y da ma ge wit h  n or mal or ↑ ↓ G F R  ≥  9 0  
2  Ki d ne y da ma ge wit h mil d ↓ G F R  6 0 -8 9  
3  M o derate ↓ G F R  3 0 -5 9  
4  Se vere ↓ G F R  1 5 -2 9  
5  Ki d ne y fail ure  <  1 5 ( or dial ysis)  
 
Ac ute ki d ne y i nj ur y sta ges base d o n t he D efi niti o n b y t he A c ute Ki d ne y I nj ur y N et w or k ( A KI N) ar e o utli ne d i n Ta ble 3 (K DI G O Cli nical Practice G ui deli ne f or A KI, 2 0 1 2 ). 
T a bl e  3 . Cl a s sifi c ati o n/ St a gi n g S y st e m f or A c ut e Ki d n e y I nj ur y
 
St a ge  Ser u m cre ati ni ne criteri a  Uri ne o ut p ut criteri a  
1  1. 5 t o 1. 9 ti mes baseli ne or ≥  0. 3 m g/ d L ( ≥  2 6. 5  µ m ol/ L) i ncrease fr o m 
baseli ne  < 0. 5 m L/ k g / h f or 6 t o 1 2 h  
2  2. 0 t o 2. 9 ti mes baseli ne  <  0. 5 m L/ k g / h f or ≥  1 2 h  
3  3. 0 ti mes baseli ne , or 
I ncrease i n ser u m creati ni ne t o ≥ 4. 0 m g/ d L ( ≥ 3 5 3. 6 µ m ol/ L) , or 
I nitiati o n of re nal re place me nt t hera p y, or 
I n patie nts <  1 8 years, decreas e i n e G F R t o <  3 5 m L / mi n per 1. 7 3 m2 <  0. 3 m L/ k g / h f or ≥  2 4 h 
or a n uria f or ≥ 1 2 h  
 
 
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665188] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 6 9  of 7 2  V 4 ( Gl o bal)  
 A p p e n di x 4   E sti m ati n g G F R a n d C orr e cti n g C al ci u m  
e G F R  
T he e q uati o n f or esti mati n g gl o mer ular filtrati o n r ate ( G F R) fr o m ser u m cr eati ni ne is t he 
is ot o pe dil uti o n mass s pectr o metr y (I D M S)-tracea ble M o dificati o n of Diet i n Re nal Disease ( M D R D) st u d y e q uati o n. T his e G F R calc ulat or a p plies ser u m crea ti ni ne ( Scr) r e p orte d i n m g/ d L.  
T he e G F R s h o ul d be calc ulate d base d o n f oll o wi n g e q u ati o n  e G F R ( m L/ mi n/ 1. 7 3 m
2) = 1 7 5 x ( Scr)-1. 1 5 4 × ( A ge)-0. 2 0 3 x ( 0. 7 4 2 if fe male) x ( 1. 2 1 2 if 
Africa n A merica n)  T he e G F R  f or J a pa nese s u bjects s h o ul d be calc ul ate d base d o n f oll o wi n g e q uati o n (Mats u o et 
al., 2 0 0 9) : 
e G F R ( m L/ mi n/ 1. 7 3 m
2) = 1 9 4 × ( Scr )-1. 0 9 4 × ( A ge)-0. 2 8 7× ( 0. 7 3 9 if f e male)  
C orrecte d Ser u m C alci u m  
C orrecte d s er u m cal ci u m = 0. 8 * [ 4 g/ d L – meas ur e d ser u m al b u mi n [i n g/ d L]) + meas ure d 
calci u m [i n m g/ d L]  
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665189] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 7 0  of 7 2  V 4 ( Gl o bal)  
 A p p e n di x [ADDRESS_665190] u d y will als o be pr o hi bite d as a c o n c o mita nt me dicati o n i n t his pr ot oc ol. 
Ge neric N a me  Tr a de N a me  
ca na glifl ozi n  I n v o k a na™  
ca na glifl ozi n pl us metf or mi n  I n v o k a met™  
da pa glifl ozi n  Far xi ga ™  or F or xi ga ™  
e m pa glifl ozi n J ar dia nce
® 
e m pa glifl ozi n pl us li na gli pti n  Gl y x a m bi® 
e m pa glifl ozi n/ metf or mi n H Cl  S y njar d y  da pa glifl ozi n/ metf or mi n H Cl 
e xte n de d releas e ta blet  Xi g d u o X R  
	
  1 0/ 2 7/ 2 0 1 6
B e xa glifl ozi n T a blets   T herac os S u b, L L C  
Cli nical Trial Pr ot oc ol : T H R -[ADDRESS_665191] o ber 2 0 1 6   
   
 
C o nfi de ntial  P a ge 7 2  of 7 2  V 4 ( Gl o bal)  
 A p p e n di x 7   I n v e sti g at or’ s Si g n at ur e 
St u d y  Title:  A d o u ble bli n d place b o c o ntr olle d st u d y t o e val u ate t he effect of 
be x a glifl ozi n ta blets o n he m o gl o bi n A 1c i n p atie nts wit h t y pe [ADDRESS_665192] u d y  N u m ber:  T H R -1 4 4 2 -C -4 4 8  
Fi n al  D ate:  [ADDRESS_665193] y wit h t he I nter n ati o nal C o nfere n ce o n Har m o nisati o n (I C H) Tri partite g ui deli ne o n G o o d Cli nical Practice ( G C P) a n d all a p plica ble r e g ulati o ns a n d t o c o n d uct t he st u d y as descri be d i n t he pr ot o c ol.  
I a gree t o e ns ur e t hat Fi n a ncial Discl os ure State m e nts will be c o m plete d b y m yself a n d m y 
s u bi n vesti gat ors at t he st art of t he st u d y a n d f or u p t o [ADDRESS_665194] of t he cli nical i n vesti gati o n wit h o ut t he pri or writte n c o ns e nt of T herac os S u b, L L C.  
    Si g ne d:    Date:     
Pri nci pal I n vesti gat or  
 
   